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POPULAR SCIENCE SUMMARY OF THE THESIS 
As the population grows older, people endure more and more long-term health problems 
acquired throughout their lives. This presence of multiple chronic disorders in an individual – 
“multimorbidity” poses a significant problem, as the interaction between the disorders makes 
treatment and care more difficult. One of the most serious chronic conditions is dementia, a 
heterogeneous group of disorders affecting the brain and leading to dependency on 
caregivers. More than 50 million people suffer from dementia today, most commonly due to 
Alzheimer’s disease. Currently, the available medications do not stop the progress of 
dementia, thus the management of risk factors and improving the clinical care becomes 
crucial.     
Importantly, diabetes mellitus (DM) is among the most significant risk factors for dementia. 
DM is typically recognized by its cardinal sign – high blood sugar, however it is a complex 
disorder, affecting the whole body including the brain. There are approximately 460 million 
patients living with DM worldwide, which leaves a huge number of people at increased risk 
of dementia. Indeed, a large proportion of patients suffering from dementia have concurrent 
diagnosis of DM, however we do not have a clear understanding what constitutes the best 
practice for these patients.  
In this thesis, we focus on the clinical and pharmacological care patients who suffer from 
both DM and dementia receive in Sweden.  
In the studies 1 and 2, we found that the symptomatic medications used in dementia help in 
prolonging survival, however they are prescribed less frequently in patients who suffer from 
both DM and dementia. In study 3, we conclude that the presence of dementia diagnosis may 
modify how DM is treated, which was reflected in more frequent use of insulin. Additionally, 
in study 4 we found that certain DM medications, like sodium-glucose cotransporter-2 
inhibitors are associated with better survival in patients with dementia. Finally, in study 5 we 
concluded that DM medications metformin and dipeptidyl-peptidase-4 inhibitors can be 
cognitively protective in patients with dementia. 
In summary, we found that the patients who suffer from both DM and dementia are a unique 
group that can benefit from the symptomatic medications used for dementia. Furthermore, we 
suggest which treatments for DM can have a positive impact on survival and cognition in 






Diabetes mellitus (DM) and dementia are frequent chronic disorders in the older population, 
however their relationship is complex - while DM is an established risk factor for dementia, 
cognitive symptoms in dementia may hinder the self-management essential in DM care. 
Importantly, the co-occurrence of DM and dementia is common in clinical practice, however 
the research examining patients suffering from both disorders is scarce. This thesis analyzes 
the bidirectional associations between DM and dementia in patients with both disorders in 
Sweden, with specific focus on pharmacological care. 
The thesis is based on the merged data from the Swedish Dementia Registry and the Swedish 
Prescribed Drug Register, Swedish National Patient Register, Swedish Cause of Death 
Register, Total Population Register and the Longitudinal Integrated Database for Health 
Insurance and Labour Market Studies. All included studies were observational, study 1 was 
cross-sectional and in studies 2-5 longitudinal open-cohort design was used.  
Study 1 compares the characteristics of patients with DM and dementia to patients without 
DM. We show that DM is prevalent in 16.5% of patients with dementia, and that DM is 
associated with diagnosis at younger age, vascular dementia and mixed-pathology dementia 
(MixDem), and less frequent use of cholinesterase inhibitors (ChEI) and memantine. 
In study 2 we analyze the association between ChEI and mortality in patients with DM and 
Alzheimer’s disease (AD) or MixDem. We show that the initiation of ChEI class, donepezil 
and galantamine is associated with lower all-cause mortality, and the direction and strength of 
the association is comparable to DM-free patients.  
Study 3 explores the changes in long-term utilization of antidiabetic medication in patients 
with type 2 DM or other/unspecified DM with and without dementia. We conclude that 
utilization as well as new dispensation of insulin is significantly higher among patients with 
dementia, while the newer antidiabetic drugs are less commonly prescribed.  
Study 4 compares the mortality risk associated with six major antidiabetic drugs in patients 
with type 2 DM or other/unspecified DM and with and without dementia diagnosis. Overall, 
the initiation of insulin in patients with type 2 DM or other/unspecified DM is associated with 
higher mortality, regardless of dementia status. Additionally, we observe lower mortality in 
patients with dementia who used sodium-glucose cotransporter-2 inhibitors (SGLT-2i). 
Lastly, study 5 examines whether the use of antidiabetic medications is associated with 
longitudinal changes in Mini-Mental State Examination (MMSE) scores in patients with AD 
or MixDem. Importantly, we conclude slower decline in MMSE scores among users of 
metformin and dipeptidyl-peptidase-4 inhibitors. 
In conclusion, the patients with DM and dementia constitute a unique cohort less likely to 
receive treatment with ChEI despite the observed lower mortality associated with ChEI in our 
and previous studies. Moreover, we describe higher utilization of insulin and lower use of 
newer antidiabetic medications in patients with dementia, reflecting the Swedish clinical 
approach. Furthermore, we suggest that antidiabetic medications may provide cognitive 
benefit in patients with AD or MixDem. Additional studies focusing on optimization of 
antidiabetic and dementia medication, glycemic control as well as cognitive changes are 
needed to disentangle the role of DM in patients with manifest dementia. 
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1.1 DEMENTIA AND DIABETES – PARTNERS IN CRIME 
More than 100 years have passed since Alois Alzheimer described the characteristics of the 
most common dementia type worldwide1, while the first mention of diabetes mellitus (DM) 
may reach as far as 1500 BC2. Despite such extensive history, the notion that DM and 
dementia may be connected has only developed in the last three decades. Since, DM has been 
recognized as an independent risk factor for dementia3, while cognitive impairment has major 
influence on the patients’ ability to manage DM4. Moreover, the rise in life-expectancy5, the 
obesity epidemic6 and improvements in the treatments of chronic disorders all contribute to 
the increasing co-occurence of both disorders in one patient7. However, there is insufficient 
knowledge to guide clinical reasoning in such situation.  
In this thesis, we focus on the clinical and pharmacological management of DM and dementia 


















2 LITERATURE REVIEW 
2.1 DEMENTIA 
Dementia comprises heterogeneous group of disorders, and is best characterized by cognitive 
or behavioral impairment of such extent, that it interferes with daily activities8-11. According 
to the NIA-AA criteria11, impairment must involve minimum two of the following domains: 
1. Impaired ability to acquire new information (memory impairment) 
2. Impaired reasoning and handling of complex tasks, poor judgment 
3. Impaired visuospatial ability  
4. Impaired language functions (speaking, reading, writing) 
5. Changes in personality, behaviour or comportment 
When the impairment does not interfere with daily activities, but the cognitive performance is 
objectively lower than is appropriate for the patient’s age and education, there a diagnosis of 
mild cognitive impairment (MCI) is suitable12. Risk factors for different disorders are often 
overlapping, suggesting common pathological pathways between dementia types3, 13. 
Some classifications introduced new nomenclature for dementia (e.g. DSM-V), however we 
keep the current wording in line with previous studies and current International Classification 
of Disorders, while acknowledging that the word “dementia” has negative connotation and 
may lead to stigma14. 
The review is focused on the main types included in the thesis’ studies and does not comprise 
relatively newer LATE15 or less common dementia types.  
2.1.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with heterogeneous 
etiology and the most frequent dementia disorder responsible for 60-70% of all dementia 
cases9. Age is the most important risk factor for AD, however there is a plethora of genetic, 
sociodemographic, vascular / metabolic and lifestyle factors that contribute to AD risk9, 16.  
AD is typically divided by the age of onset into early-onset (≤65 years) and late-onset (>65 
years) AD. Late-onset AD (sporadic AD) constitutes the majority of AD cases, with the most 
important genetic risk factor being the epsilon-4 allele of the apolipoprotein-E17, particularly 
in homozygous constellation. On the other hand, several genetic risk factors have been 
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identified for early-onset AD (<10% of cases), while heredity and family clustering are more 
frequent in this AD type18. The main AD-relevant genes include APP, PSEN1 and PSEN2 18.  
The clinical criteria for probable AD11 include the impairment in cognition and behaviour as 
described in the section on dementia, with additional conditions including: 
1. Insidious onset (months to years) 
2. Clear-cut history of cognitive worsening  
3. Cognitive deficits most prominent either in learning and recall of recently 
learned information (amnestic presentation) or 
4. Cognitive deficits in language, visuospatial domain or executive 
functioning (non-amnestic presentations) 
5. No evidence of other disorders that have a substantial effect on cognition  
The main pathological hallmarks of AD include the accumulation of the toxic β-amyloid 
fibrils (intracellular and extracellular) and hyperphosphorylation of τ-protein (intracellular), 
which lead to progressive neurodegeneration with loss of synaptic function, neuronal loss, 
clinical dementia and disability. The predominant amyloid cascade hypothesis19 sets the 
aggregation and deposition of β-amyloid in plaques as the primary event which subsequently 
leads to neurofibrillary tangles (constituting the hyperphosphorylated τ-protein) and 
neurodegeneration. The current research framework for AD diagnosis [the AT(N)] also 
stressed the role of abnormal amyloid metabolism at the beginning of the pathological 
process of neurodegeneration and dementia due to AD20.  
However, amyloid deposition may be present even in patients without cognitive symptoms21 
and the temporal relationship between β-amyloid deposition and neurofibrillary tangles has 
not always been observed22.  
The pathological process of neurodegeneration very likely begins decades prior to the onset 
of clinical symptoms, with first detectable biomarkers of β-amyloid deposition, followed by 
biomarkers of τ hyperphosphorylation, brain structure changes and neurodegeneration and 
finally, objective decline in cognitive functioning23. 
The complexity of the disease, combined with long preclinical stage has contributed to the 
unprecedented failure in pharmacological research24, and no disease-modifying treatments 
exist for patients with AD. 
Currently, the cognitive symptoms are treated with cholinesterase inhibitors (ChEI) in mild-




AD, alone or in combination with ChEI25. Moreover, their effect is only symptomatic, and the 
strength of the cognitive stabilization is modest 26. 
However, improvements in the diagnostic process, including positron-emission tomography, 
advanced magnetic-resonance imaging techniques and recent findings on blood-based 
biomarkers of β-amyloid metabolism27 are encouraging and will contribute to higher 
precision of patient sampling for randomized clinical trials. 
2.1.2 Vascular dementia 
Vascular dementia (VaD) is commonly mentioned as the second most frequent dementia 
disorder with increasing prevalence with advancing age28, however pure vascular phenotype 
is present only in less than <10% of cases13 and mixed pathologies are more common13, 29. 
Moreover, VaD represents only the end of the pathogenetical continuum, thus the term 
vascular cognitive impairment was coined to reflect the whole process from preclinical stages 
to VaD (“major vascular cognitive impairment” is also used as synonym for VaD)13.  
The main risk factors for VaD include sociodemographic characteristics (higher age, female 
sex, lower education), chronic disorders (e.g. hypertension, dyslipidaemia, DM, stroke) and 
genetic and lifestyle factors (smoking, physical inactivity)13. The common presence of both 
AD and vascular pathologies is also reflected in the communality of risk factors for AD and 
VaD3, 13.  
The clinical picture is much more variable than in AD, as the impairment depends on the 
affected brain substrate. Typically, impairments in attention, information processing, 
executive function and memory are present29. In addition, the behavioural symptoms 
including apathy, anxiety and depression are common, as well as other neurological deficits -  
parkinsonism, urinary incontinence and language impairment13. The overall survival in VaD 
is lower compared to AD and varies between 3-5 years29, 30. 
Magnetic resonance imaging constitutes the gold standard in diagnosis vascular cognitive 
impairment13, 29 and both cerebral large vessel and small vessel diseases are observed in VaD 
13.  
The AHA/ASA13 criteria for VaD comprise:  
1. Observed decline in cognitive functioning in at least two cognitive domains 
sufficient to affect individual’s activities of daily living. 
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2. Executive function, memory, attention, language and visuospatial 
functioning should be assessed before establishing VaD diagnosis. 
3. Deficits in activities of daily living are independent of the motoric and 
sensory symptoms of the vascular event. 
The management of VaD is mostly focused on primary and secondary cardiovascular and 
cerebrovascular prevention25. Moreover, some degree of evidence suggests the use of ChEI 
mainly in patients with specific MRI findings and concurrent AD13. Multidisciplinary patient-
approach is often necessary due to varying clinical features.  
2.1.3 Mixed-pathology dementia 
Mixed-pathology dementia (MixDem) is not universally recognized as a specific dementia 
type, however the presence of multiple pathologies is very common in the older population31. 
For the purpose of this thesis, we considered MixDem as the combination of AD and vascular 
pathology32 and such combination may be responsbile for up to 20% of dementia cases33. 
2.1.4 Lewy body dementias 
Lewy body dementias is an umbrella term for two dementia types - dementia in Parkinson’s 
disease (PDD) and dementia with Lewy bodies (DLB). which are common in patients >65 
years of age34. The main difference between PDD and DLB lies in the onset of 
symptomatology, where PDD presents first with motor symptoms (bradykinesia, tremor, 
rigidity) whereas dementia develops before or within 1 year of parkinsonism onset in DLB34, 
35. The main connecting pathology is the presence of alfa-synuclein inclusions in the neurons, 
accompanied by neuronal death34. 
DLB: This specific dementia type is considered the third most common after AD and 
vascular dementia36 and is commonly underdiagnosed in clinical practice34. One of the 
common traits with AD is the increased risk of DLB in Apo-E epsilon-4 carriers34, 37, and the 
overlap with AD in pathogenesis and co-occurence is large overall37. Clinically, it may be 
difficult to distinguish between DLB and AD37, however the presence of visuospatial deficits 
or visual hallucinations is highly indicative of DLB 34. 
Diagnostic features of DLB:  
1. Central feature  – dementia presenting by deficit in attention and executive 
function. 
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2. Core features – fluctuating cognition, recurrent visual hallucinations,
spontaneous features of parkinsonism.
3. Suggestive features – REM sleep behaviour disorder, low dopamine
transporter uptake in basal ganglia, neuroleptic sensitivity.
4. Supported features (not considered in diagnosis) – depression, systematized
desillusions, repeated falls and syncope.
PDD: Patients with PD commonly present with cognitive symptoms, and it is estimated that 
up to 80% progress to dementia38. For diagnosis of PDD, the onset of dementia has to occur 
in a patient with established PD, minimum 1 year after the onset of parkinsonian symptoms38.  
Diagnostic features of PDD: 
1. Core feature – diagnosis of PD and dementia in context of established PD.
2. Associated features – impairment in attention, executive and visuospatial
function, free recall; Presence of apathy, depression, halucinations and
delusions support PDD diagnosis.
3. Exclusion of vascular or cognitive/behavioural symptoms in context of
another systemic disease.
No disease-modifying treatments are available, but ChEI and memantine may provide 
cognitive alleviation in DLB and PDD25.On the other hand, antipsychotic treatment to 
manage visuospatial deficits / hallucinations should be closely monitored and doses should be 
titrated due to worsening of parkinsonism, while L-dopa may exacerbate psychosis25, 34, 39. 
2.1.5 Frontotemporal dementia 
Frontotemporal dementia (FTD) is the second most common dementia in patients below the 
age of 6540. Behavioral changes and symptom resemblance with other disorders may lead to 
missclassification and the real prevalence is underestimated 40. FTD shows signs of heredity, 
40% of all cases have positive history among first-line family members41, thus family history 
is an important step in clinical investigation. Diagnosis is supported by evidence of frontal 
and anterior temporal atrophy on neuroimaging or neuropathological investigation40. FTD is 
acompanied by neuropsychiatric symptoms and difficulties in language and speech41. 
Average life expectancy after symptom onset varies between 6-11 years, however the 
survival is substantially shorter in the behavioural variant - approximately 3 years42. 
Behavioural variant of FTD: characterized by early behavioural and executive deficits 
leading to personality changes. Typical signs include: apathy, stereotypical and compulsive 
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acting, hyperorality, executive deficits, loss of empathy, personal neglect, often inappropriate 
and offensive actions, eating disorders. 
Primary progressive aphasia: indicated by language dysfunction in early stages. 
1. Semantic variant – impairment in semantic knowledge, naming of objects
and persons, word comprehension, surface dyslexia and dysgraphia.
2. Non-fluent variant – speech apraxia, agrammatism, lingual errors
No drug treatments are currently available for FTD, and focus lies on the management of 
behavioural symptoms40. 
2.2 DIABETES 
DM constitutes a cluster of metabolic disorders connected by a common biochemical 
disturbance – hyperglycaemia. DM is a heterogeneous disorder, comprising four distinct 
types43 – type 1 DM (T1DM), type 2 DM (T2DM), gestational DM and specific DM. The 
main characteristics of T1DM and T2DM are summarized in Table 1. 
Table 1. Characteristics of the two main DM types 
Type 1 DM43 Type 2 DM43 
Autoimmune or idiopathic disorder 
(destruction of β-cells in pancreas) 
Peripheral insulin resistance & 
β-cell dysfunction 
Absolute insulin deficiency Relative insulin deficiency 
Present autoantibodies (most cases) No autoimmune reaction 
Diabetic ketoacidosis common Obesity & overweight common 
5-10% of cases 90-95% of cases
Insulin treatment essential Insulin treatment optional 
T1DM and T2DM are responsible for most cases (prevalent and incident) of DM, while the 
gestational DM (diagnosed during pregnancy) and specific DM (e.g. after cystic fibrosis) are 
less common. The diagnosis of DM is based on the evaluation of glucose metabolism, either 
using concentration of venous glucose or proportion of haemoglobin A1c in blood43. DM is 
confirmed in patient with:  
1. Fasting glucose of >7.0 mmol/l or




3. Haemoglobin A1c concentration >48 mmol/mol or  
4. Random plasma glucose >11.1 mmol/l in patient with typical DM symptoms. 
Prediabetes is a term used in patients without normal glycaemia who do not fulfil the criteria 
for DM. Prediabetes is identified in patients with43: 
1. Fasting glucose between 5.6 - 6.9 mmol/l or 
2. Glucose between 7.8 - 11.0 mmol/l at 2 hours during the oral glucose tolerance 
test or 
3. Hemoglobin A1c concentration 39-47 mmol/mol 
The onset of DM is often insidious (particularly in T2DM), with long prediabetes period, and 
patients with prediabetes have a higher risk of DM diagnosis43. Additionally, the presence of 
DM is associated with substantial microvascular (retinopathy, neuropathy, nephropathy) and 
macrovascular complications (accelerated atherosclerosis, heart failure, myocardial 
infarction, peripheral arterial disease)44, 45, primarily depending on the level of control and 
duration of the disease. The treatment of DM varies between types, with insulin being the 
essential drug for T1DM patients, while lifestyle and diet adaptations, with or without 
medication therapy is used for T2DM treatment46. Importantly, DM is a common 
comorbidity in the older population, with approximately 25% of the population >65 years old 
affected4.  
2.3 EPIDEMIOLOGICAL LINKS BETWEEN DIABETES AND DEMENTIA 
2.3.1 Type 1 diabetes 
Compared to T2DM, T1DM is much less prevalent among patients with dementia, however 
with increasing life-expectancy of patients with T1DM47, the clinical co-occurrence of T1DM 
and dementia diagnosis will become more frequent. T1DM has been associated with specific 
deficits in cognitive domains (sparing memory)48, higher overall risk of dementia49 and 
multiple mechanisms linked with cognitive decline49, 50. 
While a small percentage of patients included in the thesis’ studies likely had T1DM, the 
patients were not analysed separately and studies 3-5 excluded patients with T1DM, making 
the generalisations to T1DM difficult. Consequently, in the subsequent sections, we describe 
primarily the relationships between T2DM or overall DM and dementia. 
2.3.2 Type 2 diabetes 
T2DM is considered a modifiable risk factor for dementia, but the nature of the relationship 
varies between the different dementia disorders. 
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Overall dementia, Alzheimer’s disease, vascular dementia: The connection between 
T2DM and the most common dementia types has been first notioned in the late 90’s with 
cross-sectional studies51, 52, and the Rotterdam cohort study reporting twice the risk of 
dementia, AD and VaD in T2DM patients53. Luchsinger and colleagues corroborated the 
increased risk of AD in DM54. Conversely, the Swedish Kungsholmen study found no 
significant risk increase for AD55, but later evaulation found even the prediabetic stages 
indicative of AD and dementia56. The Honolulu-Asia Aging Study observed the interaction 
between T2DM and apolipoprotein E genotype, a separate link between T2DM and AD57. 
Subsequently, the review of 14 cohorts by Biessels and colleagues has provided a reasonable 
indication on how strong the pooled dementia risk is in T2DM patients, with twice the risk 
for incident dementia, approximately 75% increase in risk for AD and 125% increase for 
VaD58. These estimates were further updated by Chatterjee and colleagues who concluded 
68% increase in overall dementia risk, and differentially higher VaD risk in women (134% 
higher) than in men (73% higher)59.    
Further research by Kloppenborg and colleagues showed that 1 in 10-15 cases of dementia 
could be attributable to T2DM60. This was updated by Livingston and colleauges, who 
described 12 modifiable factors (Table 2) responsible for 40% of dementia cases, with 
T2DM independently responsible for every 100th case of dementia3. 
Table 2. Modifiable risk factors for dementia in different ages 
 Relative risk for 
dementia 
Communality Weighted population 
attributable fraction 
Early life (<45 years)  
  Less education 1.6 (1.3-2.0) 61.2% 7.1% 
Mid-life (45-65 years)  
  Hearing loss 1.9 (1.4-2.7) 45.6% 8.2% 
  Traumatic brain injury 1.8 (1.5-2.2) 55.2% 3.4% 
  Hypertension 1.6 (1.2-2.2) 68.3%) 1.9% 
  Alcohol intake 1.2 (1.1-1.3) 73.3% 0.8% 
  Obesity 1.6 (1.3-1.9) 58.5% 0.7% 
Later life (>65 years)  
  Smoking 1.6 (1.2-2.2) 62.3% 5.2% 
  Depression 1.9 (1.6-2.3) 69.8% 3.9% 
  Social isolation 1.6 (1.3-1.9) 28.1% 3.5% 
  Physical inactivity 1.4 (1.2-1.7) 55.2%) 1.6% 
  DM 1.5 (1.3-1.8) 71.4% 1.1% 




Communality refers to clustering of risk factors; Weighted population atributable fraction refers to the 
proportion of cases attributable to the specific factor adjusted for communality; Adapted from 
Livingston et al. Lancet (2020)3, for full table see reference. 
Overall, T2DM is a strong risk factor for dementia, AD and VaD, however the mechanistic 
relationships are not completely explained. 
Mixed-pathology dementia: Patients with T2DM suffer from higher cardio- and 
cerebrovascular burden, and the presence of both cerebral AD and vascular pathologies is 
common in this group61, 62. 
Dementia in Parkinson’s disease: Multiple studies have found T2DM to be connected to 
higher risk for Parkinson’s disease (PD)63, 64, on the other hand the connection to the 
cognitive decline associated with PD is not completely elucidated. Importantly, larger 
cognitive decrements were previously observed in DM patients with PD65, 66 and a lower 
prevalence of DM was found in patients with PDD67, possibly due to survivor bias. 
Consequently, a meta-analysis of case-control and cohort studies by Xu and colleagues found 
no association between T2DM and PDD68. The links between T2DM and PD are 
multidirectional, including insulin resistance, autophagy and inflammatory pathways69.  
Dementia with Lewy bodies: The connection between DLB and T2DM is not conclusive. 
T2DM was not associated with DLB in two studies from the United States70, 71, and one 
Swedish study found DM to be less prevalent in DLB when compared to AD67 - similar 
finding as for PDD, corroborating the communality between these two dementia types37. 
Moreover, Javanshiri concluded lower DM prevalence in the autopsy reports of patients with 
Lewy body dementias compared to other dementias, but the data were not distinguished 
between DLB and PDD72. 
Frontotemporal dementia: Due to lower overall frequency of this particular dementia type, 
few studies were performed in T2DM patients. An Argentinian case-control study of 100 
FTD patients found almost 4-fold increase in odds of FTD in T2DM subgroup73, and an 
Australian cohort found higher prevalence of T2DM in the behavioural variant of FTD, as 
well as multiple biochemical abnormalities consistent with T2DM74. Conversely, a Swedish 
registry study found no association between the two disorders67. Larger cohorts are needed to 
conclude the link. 
2.4 BIOLOGICAL CONNECTIONS 
We focus on the main connections between T2DM and different dementia types. The 
comprehensive review of the mechanisms is beyond the scope of this review. 
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Alzheimer’s disease: Compared to periphery, where insulin‘s main role is the utilization of 
glucose by peripheral tissues, the cerebral insulin serves a different function. Specifically, 
insulin affects neuronal survival by inhibiting apoptosis, modulates long-term potentiation 
and depression, synaptic health, influences the neuronal glucose uptake, modulates the 
astrocyte-neuron lactate exchange and more75, 76. There is increasing evidence of cerebral 
insulin resistance in T2DM – a parallel to the systemic insensitivity of end-organ cells to 
insulin75. Consequently, Steen and colleagues have floated the name “type 3 diabetes” for AD 
to reflect the observed changes in insulin and insulin growth factor expressions77, however 
some authors dispute the term due to lack of hyperglycorrhachia in AD78. The circumstances 
and exact pathological mechanisms of the brain insulin resistance are not clear, as T2DM 
seems to disrupt the levels of cerebral insulin in both directions (increased permeability of the 
blood-brain barrier vs. downregulation of insulin receptors due to hyperinsulinemia)75. The 
dysfunction of insulin’s natural function leads to plethora of subtle changes significantly 
affecting neuronal and glial health75. Importantly, several antidiabetic medications have been 
connected to alleviating brain insulin resistance79, 80.  
Inflammatory response constitutes a further link between T2DM and AD. Overall, T2DM is 
associated with higher levels of circulating cytokines, e.g. interleukin-6 or C-reactive 
protein81, and these circulating pro-inflammatory mediators in combination with 
hyperglycaemia may disrupt the blood-brain barrier82, 83. In addition, the activation of 
receptors for advanced-glycation products generated through hyperglycaemia may lead to 
release of inflammatory cytokines, endothelial dysfunction and cerebral ischemia76. 
Moreover, the increase in proinflammatory cytokines was also observed in hippocampi of 
DM animals84. One of the key contributing mechanisms in AD pathogenesis is the over-
activation of microglial and astroglial inflammatory reaction85, 86. Thus, it is likely that 
T2DM-AD connection includes pathological immune response.  
Additional link constitutes the Apo-E ε4 allele – most important genetic risk factor in late-
onset AD3 - considered to reduce the β-amyloid clearance and decrease the protection against 
reactive oxygen species87. Importantly, the cognitive effects of antidiabetic medications [e.g. 
metformin and dipeptidyl-peptidase-4 inhibitors (DPP-4i)] may be contingent on the ε4 
genotype88. Moreover, higher rate and amount of β-amyloid was found in T2DM-AD carriers 
of the ε4 genotype compared to non-carriers57, 89. These suggest specific T2DM links to AD.  
Multiple additional connections exist, such as oxidative stress and neuronal enzymatic 
deficiencies80, adenosin-monophosphate kinase pathway (metformin acts as an activator)90 or 




Controversially, the findings from neuropathological and biomarker studies did not find 
T2DM to increase the burden of the hallmark AD pathologies (β-amyloid accumulation and 
τ-protein hyperfosforylation), and the heightened AD risk probably stems from multiple 
interplaying processes, such as the amylin dyshomeostasis, proteotoxicity and post-
translational changes75, 82, 92. Such connection, if true, would suggest that AD due to T2DM 
might be a unique phenotype of dementia.  
Vascular dementia: The connection with T2DM and VaD include several mechanisms. 
First, the accelerated macrovascular atherosclerosis in T2DM doubles the risk for ischemic 
stroke93 and worsens the mortality rates after stroke94, while stroke is a major contributing 
factor to VaD onset29. Additionally, T2DM is typically associated with lacunar infarcts, an 
acute small subcortical infarcts in the region of one arteriole82. Importantly, both 
macrovascular and microvascular changes in T2DM contribute to increased risk of VaD58, 95, 
however T2DM contributes significant risk to the overall vascular cognitive impairment96, 
not just VaD. In addition, the MRI studies have identified cerebral small-vessel disease 
(white matter hyperintensities, cerebral microbleeds, enlarged perivascular spaces and 
microinfarcts) a likely factor in mediating the risk of cognitive damage in T2DM82. The 
volume of white matter hyperintensities was moderately increased in T2DM patients97, with 
less consistent association found in cerebral microbleeds98. Currently, there is insufficient 
data for the other small-vessel changes. 
Moreover, the mixed AD-vascular dementia is also common in T2DM, therefore it is likely 
that T2DM may accelerate both pathologies, and the resulting course of dementia may 
depend on supplementary factors, such as apo E genotype, or inflammation. 
Lewy body dementias: Multiple connections between PD and T2DM have been suggested, 
such as the nigrostriatal damage due to hyperglycemia, mitochondrial dysfunction and 
disturbances in insulin signalling69, 99. Mitochondrial damage seems to be the most consistent 
link, with changes in gene expression (e.g. PGC-1a) and associations with hyperinsulinemia 
and insulin resistance99. Reduction in insulin-like growth factor signalling and their receptor 
binding has also been suggested as a putative mechanism between Lewy body dementias and 
T2DM35. However, it is not clear whether and how T2DM disrupts cognitive function in 
PDD and DLB patients. There could be parallels with AD, however, as the inefficient action 
of insulin can alter the cognitive functioning. A separate but interesting connection is the 
possible treatment of PD using the T2DM medication (e.g. exenatide)100. 
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Frontotemporal dementia: Golimstok and colleagues have suggested several mutual 
pathways between FTD and T2DM. Specifically, the metabolic dysruptions in the insulin-
receptor rich areas in the temporal lobes, generation of τ-protein hyperfosforylation due to 
advanced glycation end-products, and bidirectional changes in glycogen synthase kinase-3 
activity73. Moreover, Ahmed and colleagues have found increased lipid markers in both 
semantic and behavioral form of FTD, as well as increased insulin levels. T2DM and FTD 
also might be connected by the aberrant eating behavior and carbohydrate consumption74. 
Additional studies should evaluate whether antidiabetic treatment affects the clinical course 
of  FTD. 
2.5 ANTIDIABETIC MEDICATION AND DEMENTIA 
Pharmacological treatment is a major part of DM management. Interestingly, there are 
multiple studies suggesting that antidiabetic medications are associated with changes in 
cognitive functioning. 
Insulin: Insulin is an endogenous peptide hormone responsible for maintaining basal and 
post-prandial glycaemia. While patients with T1DM depend on exogenous insulin, it is not 
the first choice in T2DM treatment46. Importantly, insulin is the most potent antidiabetic 
drug, with high clearance of blood glycemia after injection101. Insulin’s potency might be 
a double-edged sword in dementia patients, where hypoglycemic episodes depend on 
cognitive function102, 103. Older insulin formulations have reduced microvascular 
complications and all-cause mortality in general DM population46. 
Insulin has pleiotropic action in neurons and glia75, however systemic insulin administration 
has not been associated with improvements in cognitive functioning104-106. Additionally, 
intranasal insulin administration has been evaluated for AD, however Craft and colleagues 
concluded lack of cognitive benefit79 despite no safety issues and improvement on MRI 
markers107-109.  
Biguanides: Metformin is the first-line therapy for T2DM, functioning as an insulin 
senzitizer, with additional pleiotropic effects dependent on the adenosin monophosphate-
kinase pathway110. Metformin reduces weight and cardiovascular mortality in T2DM46 and is 
considered safe to use in the elderly population without major decrease in glomerulal 
filtration rates4. Preclinical studies suggest neuroprotective properties in metformin111. On the 
other hand, studies in humans on dementia and cognition are controversial. Taiwanese cohort 
study found reductions in incident dementia in metformin users112, however a case-control 




users with large number of prescriptions113. On the other hand, Orkaby and colleagues 
compared sulfonylurea treatment to metformin in the US veterans and found lower hazard of 
dementia in metformin users in the <75 years old subgroup114. In addition, the 2016 meta-
analysis concluded lower risk of incident dementia in insulin senzitizers, but the effect was 
borderline insignificant115. 
Furthermore, Dominguez and colleagues have shown some cognitive benefit of metformin 
use in a small sample of AD patients116. In addition, metformin has been evaluated in MCI, 
with divergent results on the two cognitive outcomes117. The authors stated that a multi-
centered trial might be necessary to enable faster recruitment and better stratification of 
patients.  
Sulfonylurea derivates: Sulfonylureas lower blood glucose by increasing pancreatic 
production of insulin118, however the current clinical guidelines warn of possible 
hypoglycemic risk associated with their use in the elderly T2DM patients4. Moreover a study 
from the United States reported a high prevalence of sulfonylurea and / or insulin treatment in 
patients with tight glycemic control and dementia119. Some observational studies found 
increased all-cause and specific-cause mortality rates in sulfonylurea and insulin treatment, 
however this was not confirmed in high-quality clinical trials120. Similarly, Hsu and 
colleagues reported reduction in dementia risk in sulfonylurea users112, but the connection 
was not confirmed in the randomized setting106. The use of sulfonylurea derivates in T2DM 
elderly patients seem warranted, however its use might be restricted where hypoglycemic 
episodes are a possibility120 and short-term agents such as glipizide are preferred4. 
Thiazolidinediones: Thiazolidinediones (TZD) are insulin sensitizers, and act through the 
activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Currently, 
the only TZD approved is pioglitazone, however its use in the elderly is questionable, mainly 
due to the higher risk of myocardial infarction, congestive heart failure and falls4, 46.  
Similarly to metformin, TZD were associated with lower risk of overall dementia in a 2016 
meta-analysis115. Moreover, the PPAR-gamma activation in TZD, its relation to the 
transcriptional factor PGC-1a (mitochondrial dysfunction in PD) and protection against 
neurodegeneration in animal studies99 led to a well-designed, but unsuccesful clinical trial of 
pioglitazone vs placebo in early PD121.  
Incretin system: This group comprises the glucagon-like peptide-1 receptor agonists (GLP-
1a) and dipeptidyl-peptidase-4 inhibitors (DPP-4i). They function either through direct 
activation of the GLP-1 receptor (GLP-1a) or inhibition of the dipeptidyl-peptidase-4 - the 
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enzyme that inactivates GLP-1 (DPP-4i). GLP-1’s primary role is the food intake-related 
enhancement of insulin secretion, thus these drugs do not increase the risk of hypoglycemia 
122.  
GLP-1 receptors are located in multiple organs, including the brain122, and GLP-1a are 
known to pass the blood-brain barrier111. They are currently one of the most promising 
T2DM treatments displaying good glycemic control, with multiple beneficial supplementary 
effects, such as weight loss, no risk of hypoglycemia and protection in atherosclerotic 
cardiovascular disease46. Moreover, neuroprotective, anti-inflammatory and prosurvival 
effects were observed in animal studies111, 123, 124. This resulted in the 6-month clinical trial of 
liraglutide in 38 AD patients, that has shown stabilisation of glucose metabolism in multiple 
brain regions compared to placebo125, however the study could not evaluate AD biomarkers. 
Currently, the ELAD clinical trial on 12-month treatment with liraglutide is in the analytical 
stage, with cognitive and AD-pathognomical markers as primary outcomes126. Moreover, the 
results of a 60-week clinical trial with exenatide in PD were published, concluding modest 
but significant long-term improvement of PD symptoms, potentially marking a new era in PD 
treatment (the trial is continuing in phase 3)127.  
The use of GLP-1a is generally tolerated, however the adverse reactions (vomiting, diarrhea) 
and their dependence on good visual and motor functions due to subcutaneous application 
might be a problem for patients with moderate and severe cognitive impairment. The oral 
form of semaglutide may provide an efficacous alternative128.  
DPP-4i prolong the activity of endogenous GLP-1, stabilizing glycemic level similarly to 
GLP-1a122. However, they have smaller glucose-lowering efficacy, and were not found to 
exhibit cardiovascular protection46. In addition they seem to increase the propensity of 
sulfonylurea medication to cause hypoglycemia, thus closer monitoring is necessary46. On the 
other hand, DPP-4i are applied orally and have fewer side effects compared to GLP-1a, 
which might benefit the elderly and cognitively frail patients.  
Similarly to GLP-1a, DPP-4i – sitagliptin and linagliptin were found to provide cognitive 
benefit in both animal and observational studies129, however the CARMELINA-COG trial 
has not concluded any difference in cognitive functioning of linagliptin compared to placebo 
over 2.5 years130. 
Sodium-glucose cotransporter-2 inhibitors: One of the latest additions to T2DM drug 
arsenal are the sodium-glucose cotransporter-2 inhibitors (SGLT-2i), which enhance urinary 
excretion of glucose. SGLT-2i are completely dependent on kidney function, thus 




efficient in lowering glycemia, and provide multiple additional benefits, including weight 
loss, reductions in blood pressure and mortality, renal protection, and cardiovascular 
protection46, 131-133. These do not seem to be mediated through endotelial function134. 
Conversely, the adverse effects of mycotic urinary infections, reports of diabetic ketoacidosis, 
dehydration and limb amputations (in canagliflozin)46 have somewhat counterbalanced the 
success of SGLT-2i therapy. In addition, long-term monitoring of SGLT-2i will provide data 
whether their efficacy is present also in the elderly or dementia populations. However, the 
SGLT-2i dependence on kidney function and tendencies towards dehydration might 
predispose them to healthier patient population.  
Animal studies of empagliflozin have suggested improvements in cognitive functioning by 
reduction of cerebral oxidative stress, brain atrophy and BDNF increase135, 136. Moreover,  in 
a small randomized-controlled trial, SGLT-2i were comparably effective to incretins in 
cognitive performance during 12 months137. Empagliflozin’s cerebral metabolism effect is 
being evaluated in a phase 1 trial concentrating on ketone generation (NCT0385290). 
2.6 ANTI-DEMENTIA MEDICATION AND DIABETES 
Currently, no disease-modifying treatment is available for cognitive decline in AD, and the 
only approved pharmacological therapy is symptomatic and limited to ChEI (donepezil, 
rivastigmine and galantamine) used in mild-to-moderate dementia26 and the NMDA-
antagonist memantine used in moderate-to-severe dementia138. Where recognized as 
a separate dementia type (e.g. Sweden), MixDem can be treated with ChEI and memantine 
due to the present AD pathology. The treatment of VaD mainly focuses on the proper 
treatment of cerebro- and cardiovascular risk factors, such as hypertension, and 
hypercholesterolemia29, however some authors suggest donepezil even in VaD139. Due to its 
multifaceted symptomatology including neurocognitive, parkinsonian and psychiatric 
symptoms, DLB requires a careful approach39. Donepezil and rivastigmine have been 
suggested to ameliorate cognitive functioning, however the results for memantine are less 
encouraging25, 39. Similarly, rivastigmine seems to be beneficial in mild-to-moderate PDD, 
both in the capsule and patch form138. There is no approved treatment for cognitive symptoms 
in FTD140. 
It is unclear whether ChEI use provides specific benefit to DM patients, as they were not 
independently assessed in the DM subgroup. On the other hand, certain characteristics of DM 
patients and ChEI provide an insight into possible patient-specific ChEI benefit and risks. 
Specifically, cognitive deterioration impedes the proper self-management of DM141, therefore 
the ChEI’s cognitive stabilisation might provide temporary benefits for DM patients‘ ability 
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to administer their medication. However, it is unknown whether ChEI help achieve the 
hemoglobin A1c targets.  
Second, DM predisposes patients to higher likelihood of institutionalization142, 143, and the 
additional benefit of ChEI use in T2DM patients may lie in the observed delay in nursing 
home admissions144, 145.  
Third, ChEI treatment was associated with lower probability of antipsychotic prescription146, 
147, which may be particularly valuable for DM patients where managing behavioural and 
psychological symptoms (e.g. with atypical antipsychotics) can worsen DM control148.  
Furthermore, there have been several epidemiological studies reporting reduced mortality, 
cardiovascular and cerebrovascular protection associated with ChEI use149-151, primarily in 
higher doses150, 151. These findings are not completely understood, however it is reasonable to 
assume such medication effect extends to DM patients, as the mortality rates and 
cardiovascular health are generally worse in this group. On the other hand the shorter 
exposure to ChEI due to higher mortality might preclude DM patients to fully experience the 
protection, as one of the factors associated with ChEI benefit is the duration of treatment152. 
In addition, despite similar mechanism of action26, differences exist between the individual 
drugs. Donepezil is a selective and reversible ChEI with favourable safety profile153, while 
rivastigmine inhibits both acetyl- and butyrylcholinesterase, is slowly-reversible and exists as 
a capsule and transdermal patch154. Galantamine is rapidly-reversible and selective, and acts 
further as an allosteric potentiator on alpha-7 nicotinic receptors, connected to the cholinergic 
anti-inflammatory pathway155. Neuroinflammation has been linked to T2DM156 and 
galantamine’s modulation of the microglia157 could act as an additional protective factor in 
these patients. In fact, a similar anti-inflammatory modulation can be observed in donepezil, 
however the dose necessary to obtain such effect is much higher than used in clinical 
practice158.  
Conversely, adverse effects such as syncope, diarrhea and weight loss are common in all 
ChEI153. This might be detrimental especially in the very old where a degree of overweight 
might be beneficial159, however a more complicated situation may arise in T2DM patients 
where the balance between upholding glycemic control160 and increasing the risk of 
hypoglycemia161 needs to be carefully managed. The potential DM-specific benefits are 





Figure 1. Suggested benefits of ChEI in patients with DM and dementia. 
Full lines and boxes depict relationships where some evidence exists; dashed lines and boxes show 
hypothesized relationship. The figure is based on multiple studies144, 146, 148, 150, 151, 155, 157, 162, 163. 
There is limited information on the efficacy of memantine, currently the only medication 
used in moderate-to-severe AD as an addition to ChEI therapy25. Memantine has generally 
better safety profile compared to ChEI and provides small degree of cognitive stabilisation164, 
but its action is not long-lasting26. No studies have evaluated its long-term effect specifically 
in patients with DM. 
Possibly, the concerns of polypharmacy and adverse effects combined with the general 
knowledge of the symptomatic effect of AD medication may hinder their prescription in DM 
patients. Moreover, due to concerns of limited efficacy, the support for continued use of ChEI 
is decreasing in some countries165. The observational evidence of non-cognitive benefits in 
ChEI users suggests such approach may be premature.  
2.7 CLINICAL CARE OF PATIENTS WITH DIABETES AND DEMENTIA 
Both DM and dementia are connected to massive worldwide economic expenditures, 760 
billion and 1 trillion, respectively166, 167. The average survival rate of dementia patients is 
estimated between 2-7 years168, 169, and the majority of dementia-related costs are generated 
in this period due to the disease‘s progressive nature. 
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In Sweden, the long-term trend in new cases of dementia is declining170 however there are 
still approximately 130-160,000 patients living currently with dementia171, 172. Moreover, the 
last decade shows temporal improvements in mortality and risk of cardiovascular events in 
Swedish patients with dementia, probably connected to higher utilization of cardiovascular 
medication173. Additionally, there are close to 500,000 patients with DM in Sweden174, 175, 
however the research focusing on evidence-based care for patients with both DM and 
dementia is scarce.  
Multimorbidity (the presence of at least two non-communicable diseases)176 is almost 
ubiquitous in patients with dementia. Poblador-Plou and colleagues have found that dementia 
patients live with 3 additional comorbidites on average, the most common being hypertension 
and DM177. Moreover, a scoping review of 12 studies by Bunn and colleagues estimated that 
6-39% of patients with dementia have comorbid DM, with the majority of studies reporting 
the proportion between 10-20%7. When applied to the current epidemiological trend14, this 
suggests approximately 5-10 million patients live with DM and dementia worldwide.  
The current diabetes care standards consider good neurocognitive performance a significant 
prerequisite for succesful self-management of DM4. One of the major challenges in the 
elderly population with DM is hypoglycemia – the result of inadequate DM treatment. This 
can be particularly important for dementia patients, as cognitive impairment can increase the 
risk for hypoglycemia102, 178, and severe hypoglycemia predisposes patients to worse 
cognitive functioning179, 180, enclosing a vicious circle. In addition, the stringent adherence to 
glycaemic targets in the elderly has not produced cognitive benefit105 and was even associated 
with higher mortality181. Therefore the HbA1c target levels are currently adjusted and tailored 
to the functional status of the older patient4, 182. However, the standards do not provide advice 
on DM treatment as dementia advances, citing “individual re-evaluation” of glycaemic and 
cognitive outcomes.  
The progression of dementia poses a significant problem, as the recognition of hypoglycemia 
significantly decreases with advancing age183, which may be even more pronounced in severe 
stages of cognitive impairment. In addition, the capability to administer e.g. insulin or 
injectable GLP-1 agonists depends on the visual, cognitive and motor skills of the patient4. 
This might lead to lower prescription of the agents that are associated with cardiovascular 
protection46.  
Furthermore, the limited experience with the use of SGLT-2 inhibitors precludes from any 
conclusions, however their favourable cardiovascular profile131, and oral administration could 




Importantly, there are substantial obstacles when recruiting dementia patients for randomized 
control trails184, which contribute to problems when extrapolating results from the elderly 
dementia-free cohorts, or dementia patients unrepresentative of the general dementia 
population. Additionally, with no major breakthroughs in pharmacological treatment of 
dementia, the optimal management of comorbidities gains an important role in dementia care. 
Therefore, the contributions from observational studies can fill important knowledge gaps on 
patient outcomes in an understudied population.  
To conclude, managing DM in patients with dementia is a major challenge, and the clinicians 




















3 RESEARCH AIMS 
Overall aim 
The overall aim of the thesis is to determine the specific traits of patients with diabetes and 
dementia and provide longitudinal pharmacoepidemiologic evidence for the use of anti-
dementia and antidiabetic medication in this patient group. 
Specific aims 
1. To decribe the sociodemographic, clinical and pharmacological characteristics of 
patients who were diagnosed with DM and seven dementia disorders and compare 
the findings to DM-free patients (Study 1). 
 
2. To analyze the all-cause, CV and DM-related mortality associated with the use of 
overall and specific ChEI in patients with AD or MixDem dementia with or 
without concurrent diagnosis of DM (Study 2).  
 
3. To determine whether and how dementia diagnosis affects the dispensation of 
antidiabetic medication and compare the findings to patients without dementia 
(Study 3). 
 
4. To examine the differences in all-cause mortality associated with the initiation of 
six antidiabetic medications in patients with different dementia types as well as 
dementia-free subjects (Study 4). 
 
5. To compare the annual changes in MMSE scores among new and all users of 





4 MATERIALS AND METHODS 
The thesis comprises one cross-sectional and four open-cohort observational studies, based 
on the merged data from five Swedish registers and one database, specifically the Swedish 
Dementia Registry (SveDem), Swedish Prescribed Drug Register (SPDR), Swedish National 
Patient Register (NPR), Swedish Cause of Death Register (CODR), Total Population Register 
(TPR) and the Longitudinal integrated database for health insurance and labour market 
studies (LISA). Personal identity number (personnummer)185 was used to identify patients 
across sources and to merge data. The data sources and covered time intervals for each study 
are summarized in Figure 2. 
Figure 2. Registers and database used – time extent of data extracted for individual studies. 
Distances on the x axis (calendar years) are used for orientation and are only approximate 
A brief explanation of the data sources, main variable definitions, study samples and the 
statistical methods utilized are included below. For further description, please refer to the 
individual manuscripts, relevant data reports172 and publications186-192. 
4.1 SWEDISH DEMENTIA REGISTRY 
SveDem is a Swedish national quality-of-care register established in 2007 with the aim to 
register all patients with diagnosis of dementia in Sweden186.  
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Patients are registered to SveDem either from primary care, specialist memory clinic or 
nursing homes, with 78% of all primary care centers, 100% of memory clinics and 82 
municipalities covered by SveDem172. The register contains information on patients’ 
sociodemographic characteristics (e.g. age, sex), diagnostic variables [type of dementia, 
measures of cognitive functioning (e.g. MMSE scores)]193 and pharmacological treatment 
(e.g. cardiovascular medication, antidepressant use, ChEI use). Information at baseline 
registration and follow-ups (in approximately yearly intervals) is recorded186. In the end of 
2019, 91,000 unique patients were registered to SveDem172. 
Dementia diagnoses in SveDem comprise early- and late-onset AD, MixDem, VaD, DLB, 
PDD, FTD, unspecified (clinical examination to determine dementia type was not carried out) 
and other dementia types (e.g. corticobasal degeneration, normal pressure hydrocephalus). 
Diagnoses are classified according to the ICD-10, while McKeith criteria, Lund-Manchester 
criteria and Movement Disorder Society criteria were used for DLB, FTD and PDD 
diagnoses, respectively186.  
4.2 SWEDISH PRESCRIBED DRUG REGISTER 
SPDR was established in 2005 and stores data on dispensation of medications from 
pharmacies for the whole Swedish population188. SPDR contains basic sociodemographic 
data (age, sex, PIN), type of practice and profession of prescriber, and detailed information on 
the dispensation (substance name, ATC code, date of prescribing and dispensing), 
formulation and package, as well as dosage and expenditures188. Over-the-counter and 
inpatient dispensations are not included. SPDR is one of the primary sources for 
pharmacoepidemiologic studies in Sweden189.  
4.3 SWEDISH NATIONAL PATIENT REGISTER 
NPR has been operating since 1964 collecting data on inpatient somatic and psychiatric care, 
with specialized (hospital-based) outpatient care being covered since 2001187.   Registration 
to NPR is obligatory, and four categories of variables are stored: patient-related data (e.g. age, 
sex); caregiver data (hospital and department); administrative data (admission and discharge 
date); medical data (diagnoses according to the ICD system)187. The inpatient records cover 
the whole Swedish population since 1987, while the coverage of specialized outpatient care 




4.4 SWEDISH CAUSE OF DEATH REGISTER 
CODR is available in electronic format since 1952 and is used primarily for determining 
overall and specific mortality statistics in Sweden. CODR data originate from the medical 
death certificates which have to be made by the responsible physician within 3 weeks of the 
patient’s death190. Apart from the patient identifiers, the register stores data on the date and 
place of death, the underlying cause and up to 48 contributing causes of death according to 
the latest ICD coding. CODR has complete coverage for the Swedish population190. 
4.5 TOTAL POPULATION REGISTER 
TPR has been operating since 1968 and provides population statistics in Sweden, including 
births, immigration - emigration, divorce, civil status, place of residence and change of 
citizenship191. TPR is updated regularly and commonly utilized by both scientific and non-
scientific personnel191.  
4.6 LONGITUDINAL INTEGRATED DATABASE FOR HEALTH INSURANCE 
AND LABOUR MARKET STUDIES 
LISA is an annually-updated administrative database established in 1990 as a tool for 
determining changes in the labour market192. LISA comprises work-related and 
socioeconomic characteristics of the whole Swedish population older than 15 years of age.  
Information on sick leave, disability pensions, attained education, income statistics, and 
overall socioeconomic position are included192.  
4.7 DEFINITIONS AND VARIABLE TRANSFORMATIONS 
4.7.1 Diabetes 
DM variables (diagnosis, type and duration) were extracted from the NPR and SPDR.  
In study 1, DM was defined as either having a record of ICD-10 code E10-E13 in the NPR or 
a record of ATC code A10 in the SPDR from up to 3 years prior and up to 3 years after 
dementia. In studies 2-5, DM was present if either the ICD-10 code E10-E14 or dispensation 
of ATC code A10 were present prior to and including the study baseline. 
In studies 3-5, we devised an algorithm using NPR and SPDR to distinguish between T1DM, 
T2DM and other/unspecified DM. The process is summarized in Figure 3.  
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Figure 3. DM types according to the NPR and SPDR records. 
The “AND” and “OR” annotations describe the logical operations performed between the set 
conditions (I., II. & III.) for diagnosis of type 1, type 2 or other/unspecified diabetes; E10 – ICD-10 
type 1 diabetes mellitus; E-11 – ICD-10 code for type 2 diabetes mellitus; E12-E14, ICD-10 code for 
other / unspecified diabetes. 
DM duration was determined in studies 2-5 as the date difference between the earliest record 
of DM in the NPR (E10-E14) or SPDR (A10) and the study baseline.  
4.7.2 Dementia 
In study 1, all dementia diagnoses except for “other dementia” were included as registered by 
SveDem at the time of diagnosis. In studies 2 and 5, only patients with AD or MixDem were 
analyzed and in studies 3 and 4, all dementia types were included. Early- and late-onset AD 
were categorized as one group “Alzheimer’s disease” in all studies and in study 4, patients 
diagnosed with DLB and PDD were grouped together into “Lewy body dementia”. 
Additionally, MMSE scores recorded in SveDem were extracted at dementia diagnosis (all 
studies) and during follow-ups (study 5).  
Furthermore, studies 3 and 4 utilized samples of dementia-free subjects which were extracted 
from the TPR. The samples were part of a larger data extraction of subjects with dementia 
and matched dementia-free controls (original data comprised 424,624 subjects with dementia 




(=inclusion criteria for patients with dementia) were as follows: a) diagnosis of dementia in 
SveDem or b) record of ICD-10 codes F00-F03, G30, G31 in the NPR or CODR or c) record 
of ATC code N06D (anti-dementia drugs) in the SPDR; Subjects with codes F05-F09 and 
G32 were excluded from the population completely.  
From the TPR, up to four dementia-free controls were matched to subjects with dementia 
(424,624 dementia to 1,328,035 dementia-free) on birth year (± 3 years), sex, and the county 
of residence and were assigned an index date matching with the date of dementia diagnosis. 
Out of this original extraction, we included only patients with DM diagnosis (up to and 
including the study baseline) with dementia (as recorded by SveDem) or without dementia.  
4.7.3 Medication 
SPDR provided data on medication dispensation at study baseline as well as during the 
follow-up. Study baseline refers either to date of dementia diagnosis or index date in 
dementia-free subjects. SPDR comprises only filled prescriptions, thus we used the terms 
“prescription” and “dispensation” interchangeably. 
The record of ATC code and dispensation date of antidiabetic (ATC code A10), insulin 
(A10A), oral antidiabetic drugs (A10B), metformin (A10BA02), sulfonylurea (A10BB), TZD 
(A10BG), DPP-4i (A10BH), GLP-1a (A10BJ), SGLT-2i (A10BK), ChEI (N06DA – ChEI 
class, N06DA02 – donepezil, N06DA03 – rivastigmine, N06D04 - galantamine), memantine 
(N06DX01), antithrombotic (B01 and N02BA), cardiovascular (C1-C10), antipsychotic 
(N05A), antidepressant (N06A), anxiolytic (N05B) and hypnotic/sedative drugs (N05C) were 
extracted for the individual studies.  
The use of medication was binarily defined into users and non-users (study 1-5) as well as 
into users of one drug and users of other drug (studies 4 and 5). In addition, the studies 2-5 
distinguished between new users (called “incident” or “naïve” in different studies) and all 
users (“prevalent users”). Generally, the new users had no or short history of medication use 
prior to baseline, while all users could have been exposed to medication long before study 
baseline. 
Medication dispensation was the primary outcome in study 3. 
Study 1 included medication data extracted at seven time points – at the time of dementia 
diagnosis, and up to three years prior and three years after dementia diagnosis. Patients were 
considered users if a dispensation record was present at least once in any time point. Total 
number of medications at dementia diagnosis was considered a proxy for comorbidity. 
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The use of ChEI in study 2 was considered at study baseline and during follow-up. At 
baseline, patients were ChEI users if they had a record of dispensation at the time of dementia 
diagnosis (incident users) but did not have medication dispensation prior to dementia 
diagnosis - prevalent users were excluded. ChEI use was also updated on annual basis 
throughout the study follow-up (time-varying exposure) and ChEI users could transfer 
between specific ChEI. Corresponding baseline non-users were patients who were never 
prescribed medication prior to study baseline.  
Furthermore, the dose-response was analyzed using the prescribed daily doses and 
categorizing patients into low- and high-dose groups by splitting on the median prescribed 
daily dose.  
Supplementary medication (e.g. cardiovascular, antithrombotic) used in PS-matching and 
covariate adjustment  was extracted between date of dementia diagnosis and three years prior.  
In study 3, medication data functioned both to determine the outcome as well as a predictor 
and matching variables. The main outcome in study 3 was the dispensation of antidiabetic 
medication, which was defined in two ways. First, we analyzed the change in proportion of 
specific medication users (e.g. insulin, metformin) out of all antidiabetic drug users on an 
annual basis before and after the study baseline. Patients were considered users in the yearly 
period if a dispensation occurred at least once in that period. Second, in patients never 
prescribed medication prior to and including the study baseline (naïve patients), the first date 
of drug dispensation after the study baseline was of interest.  
Supplementary medications used as predictor/matching variables were extracted up to three 
years prior and including the study baseline. 
The exposure to antidiabetic drugs in study 4 was determined at baseline and during follow-
up (Figure 4). Only baseline incident users (with the first record of medication dispensation 
in the one-year period prior to and including the baseline) were included. Non-users were 
subjects without medication dispensation prior to and including the study baseline. The 
exposure was updated during follow-up in the process identical as in study 2. In addition, 
baseline users of different non-metformin medications were directly compared. For example, 
patients who were incident users of sulfonylurea, and had no history of insulin dispensation 
were compared to patients who were incident insulin users and had no history of sulfonylurea 
dispensation.   
Supplementary medications were extracted at baseline (the same way as in study 3), but the 




Finally, in study 5, both baseline incident and prevalent users of antidiabetic drugs were 
analyzed, and the definition of incident user was the same as in study 2 and 4. Non-users 
were subjects without medication dispensation prior to the baseline. Moreover, the prevalent 
baseline users of different antidiabetic medications were directly compared. Specifically, 
patients with insulin dispensation at least once prior to and including the baseline with no 
record of sulfonylurea dispensation were compared to prevalent sulfonylurea users who had 
no record of insulin dispensation. Supplementary medication was extracted the same way as 
in study 3. Medication exposure was analyzed as time-constant through the follow-up. 
Figure 4. Exposure-time assignment of the antidiabetic drug usage in study 4. 
GLD, glucose-lowering drug = antidiabetic drug. 
4.7.4 Other covariates 
Age, sex and living arrangements (living alone, cohabitating, long-term care facility) were 
obtained from SveDem for patients with dementia and TPR (dementia-free subjects). 
Chronic disorders other than DM and dementia were extracted from the NPR using ICD-10 
coding. Study 1 included diagnosis of hypertension (I10), obesity (E66) and dyslipidemia 
(E78). In studies 2-5, the comorbidities were summarized as the Charlson Comorbidity Index 
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(CCI)194, using a coding algorithm defined by Quan and colleagues195. CCI comprised the 
weighted sum of medical diagnoses up to and including the baseline (studies 2, 3 and 5) as 
well as after the baseline (study 4). Diagnosis of kidney disease was not included in the index 
in studies 3-5 and was analyzed separately. 
For study 3, the highest education attained up to the study baseline was extracted in seven 
categories from the lowest (<9 years of compulsory education completed) to the highest 
(doctoral education). Additionally, disposable individual income in Swedish Krona at study 
baseline inflated to the 2019 value using Consumer Price Index was extracted for studies 3-5 
and divided according to terciles into low, middle- and high-income categories. 
4.7.5 All-cause and specific-cause mortality 
Mortality as expressed by the record in the CODR was used to define the outcomes (studies 2 
and 4), specify competing events (study 3) and determine the range of follow-up and 
censoring (studies 2-5). 
Patient death was counted if a valid record existed in the CODR (date of death dated after the 
study baseline). For all-cause mortality statistics (studies 2-5), no distinction was made 
between underlying or contributing causes of death. In study 2, 
cardiovascular/cerebrovascular (CV) and DM-related mortality were determined if ICD-10 
codes I00-I79 and E10-E14, respectively were recorded as underlying causes of death in 
CODR.  
4.8 STUDY SAMPLES 
Study 1 and 2 focused on patients with dementia, with or without DM diagnosis. Studies 3 
and 4 comprised patients with DM, with or without dementia diagnosis. Study 5 comprised 
only patients with DM and dementia diagnosis. The study sample selection is summarized in 
Figure 5. 
The main data source in study 1 – SveDem (36,433 patients registered until December 31st, 
2013) was merged with NPR and SPDR records (Figure 2). After applying the exclusion 
criteria (Figure 5), 29,630 patients with dementia diagnosis from SveDem until December 
31st, 2012 were analyzed. In this cohort, 4,881 (16.5%) patients had diagnosis of DM and 
24,749 (83.5%) were DM-free. 
In study 2, data from SveDem (58,412 patients registered until December 31st, 2015) were 




5). In the final sample of 22,660 patients with dementia, 3,176 (14.0%) patients were 
diagnosed with DM and 19,484 (86.0%) were diabetes-free. 
Studies 3 and 4 used a subsample from a larger data extraction where both patients with 
dementia (from SveDem, NPR, CODR and SPDR) and dementia-free subjects (TPR) were 
included (Figures 2 & 5, section 4.5 on TPR). The subsample (n=138,900) comprised only 
patients with DM diagnosis who either had diagnosis of dementia from SveDem (n=13,580) 
or were dementia-free (n=171,052). Afterwards, patients with T1DM were excluded, and in 
study 4 patients with missing prognostic variables (e.g. living arrangement, dementia 
diagnosis) were also excluded. In the final sample, the study 3 comprised 133,318 patients 
and study 4 comprised 132,402 patients with T2DM or other/unspecified DM (Figure 5).  
Furthermore, in study 4, patients without history of individual antidiabetic drug use were first 
PS-matched on dementia status, then the dementia and dementia-free cohorts were analyzed 
separately. Figure 6 summarizes the study design in study 4 with sulfonylurea as example. 
In study 5, the core sample comprised patients who were diagnosed with dementia and were 
registered to SveDem until October 16th, 2018 (n=80,004). The SveDem data were merged 
with the NPR, SPDR, CODR and LISA and exclusion criteria were applied (Figure 5). We 
analyzed only patients with T2DM or other/unspecified DM who were also diagnosed with 










Figure 6. Analytical algorithm in study 4 with sulfonylurea as example. 
4.9 STATISTICAL METHODS  
Data were analyzed using IBM Statistical Package for Social Sciences (SPSS) version 23 
(IBM Corporation, Armonk NY), Stata version 16 (Stata Statistical Software: Release 16. 
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StataCorp LLC, College Station, TX), SAS version 9.4 (SAS Institute, Cary, NC) and R 
version 3.5.1 and 4.0.0196 using the packages MatchIt197 and rstpm2198.  
In all studies, continuous variables were summarized as mean [standard deviation (SD)] or 
median (interquartile range) and categorical variables as number of subjects (%). 
Independent-samples t-test, Mann-Whitney U-test and one-way ANOVA were used to 
compare continuous variables, and Fisher-exact and χ2 test were used for categorical variables 
in univariate comparisons. In addition, standardized mean differences were used to determine 
significant differences in the PS-matched cohorts. Specific methods used in individual studies 
are described below and in Table 3. For study 1, different p-value levels were used to 
determine statistical significance, between <0.05 (corresponding to 95% CI) and <0.002 
(corresponding to 99% CI). P-value <0.05 was considered statistically significant in studies 
2-5. Both time-constant and time-varying exposure models were used (depending on whether 
the exposure could change during follow-up). Study baseline refers either to date of dementia 
diagnosis or index date in dementia-free subjects. 
Study 1: Binary logistic regression was applied with DM as dependent variable and use of 
ChEI and memantine as the main explanatory variables, while stepwise adjusting for 
sociodemographic, clinical and pharmacological confounders. Odds ratios (OR) with 95% to 
99% confidence intervals marked significant associations, and the significance threshold was 
adjusted for the number of predictors/variables entered in the models (Bonferroni correction).  
Study 2: The differences among users and non-users of ChEI class and specific ChEI 
medications were balanced using propensity-score (PS) matching199 as well as regression 
covariate adjustment. Specifically, nearest-neighbor 1:1 PS-matching with caliper of 0.2 SD 
of the logit of PS was used to match on exposure status. For the survival analysis, Cox 
proportional hazard regression200 and competing risk regression201 models were used in the 
whole and matched cohorts to determine the hazard ratios (HR) with 95% CI for the 
association between use of ChEI class, donepezil, rivastigmine and galantamine and all-
cause, CV and DM-related mortality. In the competing risk regression models, other-cause 
mortality was the competing event. Time since entry was the model time scale. Time-varying 
and time-constant exposure models were used in the whole-cohort and PS-matched analysis, 
respectively. In dose-response analyses, low-dose ChEI users were the reference category. 
End of study follow-up was on August 28th, 2016. 
Study 3: Two datasets were analysed in study 3. First, a summary dataset was created where 




to the study baseline was recorded. As subjects’ diagnosis of dementia or index date varied 
between years 2007-2018 and the SPDR records started in 2005, the range of dispensations 
allowed for extraction of 14 years prior to the latest diagnosis/index date and 12 years after 
the earliest diagnosis/index date. In the summary datasert, the β coefficients with 95% CI 
from the linear regression analysis in the whole and PS-matched cohorts determined the 
changes in antidiabetic drug dispensation with yearly increments. Dementia was the main 
predictor in the model and the outcome was the change in dispensation proportion of specific 
antidiabetic drugs out of all antidiabetic drugs in the annual intervals before and after the 
index date or dementia diagnosis.   
Second, the dataset with patient-level data was analyzed. In naïve patients and in patients 
who were users of metformin in the period one-year prior to study baseline, the HR and 95% 
CI of first antidiabetic drug dispensation after study baseline was compared between 
dementia and dementia-free subjects using proportional hazards regression and competing 
risk regression models (all-cause mortality as competing event). Attained age (all main 
analyses) and time since entry (supplementary stratified analysis) were used as time scale. 
PS-matching was done using 1:1 ratio and 0.1 caliper, and exact matching was performed on 
the calendar year at dementia diagnosis / index date. Patients were followed-up until 
December 31st, 2018. 
Study 4: The use of antidiabetic medication and the risk of all-cause mortality was 
determined using a flexible parametric survival model202 with attained age as time scale  in 
the whole and PS-matched cohorts. PS-matching was performed using 1:1 and 1:4 matching 
ratios with 0.1 caliper. Patients with and without dementia were analyzed in separate 
analytical cohorts and not directly compared (Figure 6). Time-varying and time-constant 
exposure approaches were used in whole and PS-matched cohorts, respectively. Additionally, 
the presence of time-dependent confounding203 was corrected by inverse-probability 
weighting (IPW) on treatment and censoring using stabilized subject-specific time-varying 
weights – a marginal structural model was specified following a process by Fewell and 
colleagues204. Antidiabetic drug efficacy was compared in users vs non-users as well as 
between users of one drug vs users of other drug. For example, incident insulin users who 
were never exposed to sulfonylurea prior to index date were compared to new users of 
sulfonylurea who were never exposed to insulin. The study follow-up ended on December 
31st, 2018.  
Study 5: Linear mixed-effects models were applied to determine the changes in MMSE 
scores between annual follow-ups associated with the use of antidiabetic medications. 
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Analyses were done in 1:1 and 1:4 PS-matched cohorts (0.1 caliper) with the drug exposure 
as the fixed effect and the subject and follow-up time as random effects (random intercept 
and slope). Users vs non-users as well as users of one drug vs users of other drug were 
compared. Both incident- and prevalent-user analysis were performed. Last follow-up 
occurred on October 16th, 2018. 
In a sensitivity analysis, MMSE scores missing between the observed follow-ups were 
imputed using multivariate multiple imputation with chained equations based on the slope 
between observed MMSE measurements and time from baseline. Furthermore, due to 
presence of selective dropout in the source registry (SveDem), we weighted the analyses 
using IPW of remaining in the study based on MMSE in the previous observation and time 





Table 3. Summary of exposures, outcomes and statistical methods applied in the thesis’ studies. 
 Main exposures (independent variables) 
Outcomes 
(dependent variables) Main statistical tools 
Bias handling 




ChEI and memantine 
(user / non-user) 
Presence of diabetes 
(yes / no) 
Binary logistic regression Regression adjustment 
Cross-sectional 
7 dementia types 
Diabetes vs diabetes-free 
Study 2 
ChEI class & specific,  
ChEI dose-response 









AD or MixDem 
Diabetes vs diabetes-free 
Time-varying exposure 
Study 3 
Presence of dementia 
(yes / no) 
Probability and % change of  







All patients with diabetes 




(user / non-user / other user) 
All-cause mortality 




IPW – marginal structural model 
Cohort (time-to-event) 




Incident & prevalent users 
(user / non-user / other user) 
Change in MMSE scores  
during follow-up Linear mixed-effects model 
Propensity-score matching 
IPW – selective dropout 
Cohort (repeated-measures) 




4.10 ETHICAL CONSIDERATIONS 
Ethical approval was obtained for each project and the studies were permitted and approved 
by the regional ethical committee in Stockholm, Sweden (Paper 1: dnr 2013/147-31/2 & 
2016/178-32; Paper 2: 2015/743-31/4 & 2015/1313-32; Paper 3-5: 2017/501-31). All studies 
comply with the Declaration of Helsinki206. 
The notable ethical issue includes the fact that informed consent is not necessary for register-
based research in Sweden. According to the Law on Ethical Review of Research Involving 
Humans (SFS 2003:460), the research in patients with illness, psychiatric disorder or 
worsened health conditions may be performed under the condition that the research can lead 
to patient benefit and does not cause significant discomfort207. Importantly, the ethical aspects 
of individual projects are considered in detail by the regional ethical committee and the 
potential requirement of informed consent is at the committee’s discretion (i.e. the committee 
acts as ethical representative for the patients). Thus, the overall risks for the patient are low. 
Furthermore, the advantages of the register-based research (e.g. low financial demands, wide 
coverage, longitudinal data, linkage with other sources) are substantial208. In addition, it 
would be practically impossible to acquire informed consent from all subjects in the registers 
as significant proportion of high-risk patients would decline participation or would have 
already died208. Moreover, the register data are unique, and an argument could be made that 
not analyzing them may be considered unethical as the research aims to improve patient care 
and the risks are low. Additionally, the patients by law receive information about their 
registration. In SveDem, the principal register in the thesis, the patients and their relatives are 
informed orally about the registration and can decline participation. Moreover, a patient can 
ask for an excerpt of the data stored in SveDem and have their data removed from the 
register186. 
Another ethical issue arises from extent of the merged register-based datasets, that comprise 
thousands of patients and plethora of variables, which may potentially lead to patient 
identification if misused208. To this end, the anonymized data were provided to the vetted 
researchers only after the ethical application for a specific project was approved by the ethical 
committee and the possibility to reverse the anonymization was not possible. Second, the data 
were analyzed only on a group level, and no subject-level analyses were performed. 
Moreover, the data were stored and analyzed on encrypted drives managed by the central 
information-technology center at Karolinska Institutet, with restricted and password-protected 





5.1 PATIENTS WITH DIABETES AND DEMENTIA ARE LESS LIKELY TO 
RECEIVE CHOLINESTERASE INHIBITORS AND MEMANTINE (STUDY 1) 
Among 29,630 patients with dementia diagnosed until December 31st, 2015, 4,881 (16.5%) 
were also diagnosed with DM. In the fully adjusted binary logistic regression model, presence 
of DM was associated with lower age (OR 0.97, 95% CI 0.97-0.98), lower MMSE (0.98, 
0.97-0.99) and when compared to AD, more frequent MixDem (1.21, 1.06-1.39) and VaD 
(1.17, 1.01-1.36) diagnoses, while DLB (0.64, 0.44-0.94) and PDD (0.46, 0.28-0.75) were 
less frequent among DM patients (Table 4). ChEI and memantine use was less frequent in 
patients with DM (ChEI 0.77, 0.69-0.85; memantine 0.78-0.68-0.89). 
Table 4. The associations of patient characteristics with the presence of DM. 
Characteristics 
Dependent variable: Diabetes mellitus 
(4,881 DM vs 24,749 DM-free) 
Model 0; OR (95% CI) Model 2; OR (99% CI) 
Sociodemographic variables   
   Age at diagnosis, years 0.99 (0.96-0.99)* 0.97 (0.97-0.98)* 
   Male sex 1.47 (1.38-1.56)* 1.41 (1.27-1.55)* 
   Institutional living 1.15 (1.05-1.30)* 0.93 (0.74-1.18) 
   Living alone 0.91 (0.85-0.97)* 1.10 (0.99-1.22) 
Clinical determinants   
   Registered at memory clinic 0.90 (0.85-0.96)* 0.94 (0.84-1.05) 
   Total number of drugs, n 1.18 (1.17-1.19)* 1.15 (1.13-1.17)* 
   MMSE at diagnosis, points 0.99 (0.98-0.99)* 0.98 (0.97-0.99)* 
   Dementia type 
AD Reference Reference 
MixDem 1.62 (1.48-1.78)* 1.21 (1.06-1.39)* 
VaD 2.31 (2.11-2.52)* 1.17 (1.01-1.36)* 
DLB 0.80 (0.61-1.04) 0.64 (0.44-0.94)* 
FTD 1.43 (1.11-1.83)* 1.12 (0.76-1.65) 
PDD 0.82 (0.60-1.13) 0.46 (0.28-0.75)* 
Unspecified 1.47 (1.35-1.61)* 1.08 (0.93-1.25) 
Medication use   
   Antithrombotics 2.53 (2.36-2.72)* 1.18 (1.05-1.33)* 
   Cardiac drugs 1.76 (1.64-1.89)* 0.92 (0.82-1.03) 
   Antihypertensives 3.64 (3.32-4.00)* 1.96 (1.67-2.27)* 
   Statins 3.56 (3.34-3.80)* 2.29 (2.07-2.54)* 
   Antipsychotics 1.09 (1.01-1.19)* 1.08 (0.93-1.24) 
   Anxiolytics 1.10 (1.03-1.18)* 1.03 (0.91-1.15) 
   Hypnotics/sedatives 1.08 (1.01-1.15)* 0.82 (0.73-0.91)* 
   Antidepressants 1.03 (0.97-1.09) 0.85 (0.77-0.94)* 
   ChEI 0.65 (0.61-0.70)* 0.77 (0.69-0.85)* 
   Memantine 0.73 (0.67-0.80)* 0.78 (0.68-0.89)* 
Based on binary logistic regression; In the model 0, variables were entered into the model separately; 




psychotropic and dementia medication; Dementia was entered into the model as multi-categorical 
variable; The threshold for statistical significance was corrected for the number of independent 
variables entered in model 2; p-value of 0.05 was considered significant for Model 0; p-value of 0.002 
was considered significant for Model 2; *p-value <0.05 (Model 0); *p-value <0.002 (Model 2). 
 
In the fully adjusted model stratified by diagnosis of dementia (Table 5), DM diagnosis was 
associated with lower odds of ChEI and memantine use among AD patients (ChEI 0.78, 0.63-
0.95; memantine 0.68, 0.54-0.85). In MixDem and VaD patients, the negative association 
with DM was observed only for ChEI (MixDem 0.69, 0.56-0.85; VaD 0.68, 0.49-0.95). 
Table 5. Association of DM and anti-dementia drug dispensation stratified by dementia type. 
Dementia type 
Dependent variable: Diabetes mellitus 
Model 0; (OR 95% CI) Model 2; OR (99%CI) 
AD (n=9,603) 
   ChEI 0.80 (0.70-0.91)* 0.78 (0.63-0.95)† 
   Memantine 0.70 (0.60-0.81)† 0.68 (0.54-0.85)† 
MixDem (n=5,610) 
   ChEI 0.76 (0.66-0.87)† 0.69 (0.56-0.85)† 
   Memantine 0.96 (0.82-1.12) 0.86 (0.69-1.09) 
VaD (n=5,504) 
   ChEI 0.68 (0.55-0.86)* 0.68 (0.49-0.95)† 
   Memantine 1.02 (0.80-1.30) 0.99 (0.69-1.43) 
DLB (n=653) 
   ChEI 1.37 (0.75-2.51) 1.49 (0.56-3.98) 
   Memantine 0.79 (0.44-1.37) 0.71 (0.29-1.72) 
FTD (n=487) 
   ChEI 0.40 (0.14-1.15) 0.50 (0.11-2.16) 
   Memantine 0.63 (0.21-1.84) 0.36 (0.06-2.10) 
PDD (n=447) 
   ChEI 0.71 (0.38-1.33) 0.75 (0.27-2.10) 
   Memantine 0.96 (0.47-1.96) 0.84 (0.26-2.72) 
Unspecified (n=7,326) 
   ChEI 0.90 (0.79-1.03) 0.87 (0.71-1.08) 
   Memantine 0.74 (0.60-0.91)* 0.70 (0.50-0.97)† 
Binary logistic regression was used with diabetes as dependent variable and dispensation of dementia 
drugs as the main predictor; Model 0 was unadjusted; Model 2 was adjusted for sociodemographic 
characteristics, clinical characteristics (excluding dementia type), cardiovascular and psychotropic 
medication; The threshold for significance was corrected for the number of independent variables 
entered in model 2; *p-value <0.05, †p-value <0.003. 
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5.2 CHOLINESTERASE INHIBITORS ARE ASSOCIATED WITH SURVIVAL 
BENEFIT IN PATIENTS WITH DIABETES AND DEMENTIA (STUDY 2) 
In this study of 22,660 patients with AD or MixDem, 3,176 patients had diagnosis of DM 
(14%) and 19,484 were DM-free (86%). Within patients with DM 2,110 (66.4%) patients 
were ChEI users and 1,066 (33.6%) were non-users, while among DM-free 14,070 (72.2%) 
were ChEI users and 5,414 (27.8%) had no ChEI prescription at baseline. 
The use of ChEI was associated with lower all-cause mortality among both DM and DM-free 
patients with AD or MixDem in the fully adjusted whole-cohort analyses (HR 0.70, 95% CI 
0.62-0.79; DM subjects; 0.68, 0.65-0.72; DM-free subjects) and PS-matched analyses (0.76, 
0.67-0.86; DM; 0.80, 0.75-0.84; DM-free).  
In addition, only donepezil and galantamine were consistently associated with significantly 
lower all-cause mortality among patients with DM (Table 6). 
Table 6. All-cause mortality associated with ChEI use in patients with and without DM. 
 Outcome: All-cause mortality – HR (95% CI) 
ChEI  
(user vs non-user) 
Patients with diabetes & dementia 
Model 1; whole-cohort analyses PS-matched analyses 
ChEI class 0.70 (0.62-0.79)† 0.76 (0.67-0.86)† 
Donepezil 0.76 (0.66-0.88)† 0.84 (0.74-0.96)* 
Rivastigmine 0.88 (0.72-1.07) 0.97 (0.79-1.20) 
Galantamine 0.68 (0.57-0.81)† 0.80 (0.66-0.97)* 
 Diabetes-free patients with dementia 
 Model 1; whole-cohort analysis PS-matched analyses 
ChEI class 0.68 (0.65-0.72)† 0.80 (0.75-0.84)† 
Donepezil 0.69 (0.65-0.73)† 0.85 (0.80-0.90)† 
Rivastigmine 0.82 (0.75-0.89)† 1.03 (0.95-1.12) 
Galantamine 0.74 (0.69-0.80)† 0.93 (0.86-0.99)* 
Cox-regression in the whole-cohort analyses (Model 1) was adjusted for age, sex, dementia type, 
cohabitation, MMSE score, CCI, antipsychotics, hypnotics/sedatives, cardiovascular and 
antithrombotic medication, and in patients with diabetes the model was further adjusted for use of 
antidiabetic medication and diabetes duration; In PS-matched cohorts, patients were 1:1 matched 
using the same variables as in adjustment; The ChEI exposure was considered a time-varying 
covariate in adjusted model and as time-constant covariate in PS-matched analyses; *p-value <0.05; 
†p-value <0.001. 
Additionally, higher doses were not associated with additional protective effect (PS-matched 




In the whole-cohort fully adjusted analyses of specific mortality, ChEI use was associated 
with lower CV mortality, however the association was limited to DM-free patients (ChEI 
0.77, 0.69-0.85; donepezil 0.73, 0.65-0.82; rivastigmine 0.78, 0.65-0.93). Moreover, the PS-
matched analyses only confirmed the protective association in donepezil users without 
dementia (0.84, 0.75-0.94). Finally, ChEI use was associated with lower risk of diabetes-
related mortality (0.52, 0.32-0.87; DM subjects), however the association was not confirmed 
in PS-matched analyses (0.87, 0.54-1.39). The cause-specific mortality risk among ChEI 
users is summarized in Table 7. 
Table 7. CV and DM-related mortality associated with the use of ChEI.  
 Whole-cohort analyses – model 1 
 DM & Dementia 
sHR (95% CI) 
DM-free & Dementia 
sHR (95% CI) 
 CV mortality DM-related mortality CV mortality 
ChEI class 0.87 (0.69-1.08) 0.52 (0.32-0.87)* 0.77 (0.69-0.85)† 
Donepezil 0.84 (0.65-1.08) 0.56 (0.30-1.05) 0.73 (0.65-0.82)† 
Rivastigmine 0.83 (0.57-1.22) 0.46 (0.16-1.30) 0.78 (0.65-0.93)* 
Galantamine 1.11 (0.83-1.49) 0.81 (0.42-1.58) 0.98 (0.86-1.13) 
  PS-matched cohorts 
 
DM & Dementia 
sHR (95% CI) 
DM-free & Dementia 
sHR (95% CI) 
CV mortality DM-related mortality CV mortality 
ChEI class 1.02 (0.80-1.30) 0.87 (0.54-1.39) 0.92 (0.81-1.02) 
Donepezil 0.89 (0.69-1.14) 0.77 (0.47 -1.27) 0.84 (0.75-0.94)* 
Rivastigmine 0.83 (0.56 -1.24) 0.92 (0.36 -2.32) 1.06 (0.88 -1.26) 
Galantamine 1.10 (0.79 -1.54) 0.89 (0.44 -1.80) 1.05 (0.90 -1.23) 
sHR, subdistribution hazard ratio; Competing risk regression with other-cause mortality as competing 
event was used; Model 1 was adjusted for age at dementia diagnosis, sex, dementia type, cohabitation, 
Mini-Mental State Examination score, antipsychotics, hypnotics/sedatives, cardiovascular and 
antithrombotic medication and Charlson comorbidity index; Model 1 for the analysis in DM & 
dementia patients was additionally adjusted for the use of antidiabetic medication and diabetes 
duration; PS-matched analysis of ChEI was adjusted for age and MMSE in the DM-free cohort, and 
age and dementia type in the DM cohort due to residual differences in the matched cohorts; Use of 
ChEI class and specific medications were entered as time-varying exposure in whole-cohort analyses, 







5.3 PATIENTS WITH DIABETES AND DEMENTIA ARE COMMONLY TREATED 
WITH INSULIN AND LESS COMMONLY WITH NEWER DRUGS (STUDY 3) 
The third study comprised 133,318 patients with type 2 or other/unspecified DM, among 
which 12,284 (9.2%) had dementia diagnosis and 121,034 (90.8%) were dementia-free. In the 
PS-matched analyses the annual proportion of insulin use out of all antidiabetic drugs was 
more pronounced in patients with dementia compared to dementia-free subjects (1.96% vs 
0.99%, 0.97% absolute difference). On the other hand, DPP-4i (0.56% vs 1.14%, 0.58% 
difference), GLP-1a (0.13% vs 0.26%, 0.13% difference) and SGLT-2i (0.07% vs 0.28%, 
0.21%) dispensations increased, albeit less steeply in patients with dementia (Table 8, Figure 
7). The annual dispensation proportion of metformin (-1.33% vs -1.06%, 0.27% difference) 
and sulfonylurea (-1.34% vs. -1.04%, 0.30% difference) decreased more steeply in patients 
with dementia. Results were similar in the cohort using metformin in the one-year prior to 
study baseline (not shown). 
Table 8. Antidiabetic drug dispensation changes in patients with and without dementia. 
Antidiabetic 
drug 
Change in % of annual antidiabetic drug dispensation 
Dementia; β (95% CI) Dementia-free; β (95% CI) 
Absolute 
difference 
Insulin 1.96% (1.61-2.31)* 0.99% (0.82-1.15)* 0.97% (D↑) 
Metformin -1.33% (-1.64;-1.02)* -1.06% (-1.23;-0.89)* 0.27% (D↓) 
Sulfonylureas -1.34% (-1.55;-1.13)* -1.04% (-1.24; -0.84)* 0.30% (D↓) 
TZD -0.21% (-0.24;-0.17)* -0.22% (-0.25;-0.18)* 0.01 (ND↓) 
DPP-4i 0.56% (0.49; 0.64)* 1.14% (1.00-1.29)* 0.58% (ND↑) 
GLP-1a 0.13% (0.07-0.19)* 0.26% (0.17-0.35)* 0.13% (ND↑) 
SGLT-2i 0.07% (0.01-0.12)* 0.28% (0.13-0.43)* 0.21% (ND↑) 
Linear regression was used to obtain the β coefficients represent slope of change in antidiabetic drug 
usage with advancing time (one-year increments); D↑ larger percentual dispensation increase in the 
dementia cohort; D↓ larger percentual decrease in the dementia cohort; ND↑ larger percentual increase 
in dementia-free cohort; ND↓ larger percentual decrease in dementia-free cohort; Based on summary 





Figure 7. Long-term changes in antidiabetic drug dispensation in patients with diabetes and with and without dementia.  
Based on propensity score matched cohorts; The x axis - annual interval relative to dementia / index date; The y axis - proportion of specific drug users out of all antidiabetic drug 
users within the specified annual period.
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Furthermore, in the PS-matched cohorts of naïve patients (without history of medication use) 
new dispensation of insulin was more likely among patients with dementia compared to 
dementia-free (subdistribution HR 1.21, 1.11-1.31), while DPP-4i (0.72, 0.66-0.79), GLP-1a 
(0.51; 0.41-0.63) and SGLT-2i (0.44, 0.36-0.54) were less commonly prescribed to patients 
with dementia (Figure 8). Furthermore, the probabilities of new metformin (0.88, 0.77-1.02) 
and sulfonylurea dispensation (0.90, 0.76-1.07) were not significantly different among 
patients with and without dementia.  
 
Figure 8. Cumulative incidence functions of antidiabetic drug dispensation by dementia 
status in naïve patients (without previous drug dispensation).  
Figure is based on the competing risk regression models, with all-cause mortality as competing risk; 
Attained age was the time-scale and first dispensation of medication after study baseline was the 
outcome; The patients with and without dementia were PS-matched on age, sex, Charlson 
comorbidity index, renal disease, diabetes type, diabetes duration, attained education, income 
category, and use of cardiovascular, antithrombotic, antipsychotic, antidepressant, 










5.4 ANTIDIABETIC MEDICATION IS ASSOCIATED WITH DIFFERENT 
SURVIVAL IN PATIENTS WITH AND WITHOUT DEMENTIA (STUDY 4) 
In total, 132,402 subjects with type 2 DM or other/unspecified DM were included in the 
fourth study, where 11,401 (8.6%) were diagnosed with dementia and 121,001 (91.4%) were 
dementia free. 
In the flexible parametric survival model using as-treated exposure, both the patients with 
dementia (HR 1.34, 95% CI 1.23-1.45) and dementia-free subjects using insulin (1.54, 1.39-
1.71) had similarly higher risk of mortality compared to non-users (Figure 9, Table 9). 
 
Figure 9.  Antidiabetic medications and all-cause mortality by dementia status and analysis. 
In the as-treated (AT) models, use of medication was entered as time-varying exposure, while in the 
intention-to-treat (ITT) models, the exposure was time-constant. 
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Conversely, DPP-4i use was associated with lower mortality only in dementia-free subjects 
(0.71, 0.60-0.83), while no effect was observed in dementia patients (1.04, 0.90-1.20). Higher 
mortality risk was also observed among sulfonylurea users with dementia (1.19, 1.01-1.42).  
In addition, lower mortality risk was observed in GLP-1a (0.44, 0.25-0.78) and SGLT-2i 
users (0.43, 0.23-0.80) with dementia. The association in dementia-free was similar in 
strength (GLP-1a 0.68, 0.41-1.10; SGLT-2i 0.52, 0.22-1.23), however it did not reach 
statistical significance (Figure 9).  
 
Lastly, in the comparative drug-drug analyses, insulin was associated with higher mortality 
compared to sulfonylurea among dementia-free subjects (1.45, 1.02-2.06), but not in patients 
with dementia (1.17, 0.85-1.60). On the other hand, DPP-4i use exhibited lower mortality risk 
than insulin in dementia-free (0.64, 0.43-0.97), while the effect was not significant in patients 




Table 9. All-cause mortality associated with the use of antidiabetic drugs in patients with and without dementia.  
Based on flexible parametric survival models with attained age as time-scale; As-treated models were weighted using inverse-probability stabilized treatment and censoring 
weights derived from the baseline and time-updated confounders; Crude analyses were weighted but not adjusted; Adjusted analyses in the dementia-free group included baseline 
sex, comorbidity index, renal disease, diabetes type & duration, cardiovascular, antithrombotic, psychotropic and dementia medication, income and other antidiabetic medications; 
Analyses in dementia patients were further adjusted for cohabitation, dementia type and MMSE; Intention-to-treat analyses were PS-matched on baseline covariates; Medication 
exposure was analyzed as time-varying covariate in as-treated models, and as time-constant in intention-to-treat analyses; *p-value <0.05; †p-value <0.001.
Antidiabetic medication  
Crude & weighted  
as-treated analyses 




Dementia patients, HR (95% CI) 
User vs non-user 
Metformin  0.80 (0.63-1.01) 0.92 (0.74-1.13) 0.84 (0.71-1.00) 
Insulin 1.32 (1.22-1.42)† 1.34 (1.23-1.45)† 0.97 (0.82-1.15) 
SU 1.11 (0.93-1.33) 1.19 (1.01-1.42)* 1.14 (0.86-1.51) 
DPP-4i 1.05 (0.92-1.20) 1.04 (0.90-1.20) 0.88 (0.67-1.17) 
GLP-1a 0.48 (0.27-0.86)* 0.44 (0.25-0.78)* 0.48 (0.19-1.20) 
SGLT-2i 0.36 (0.19-0.71)* 0.43 (0.23-0.80)* 0.29 (0.09-0.91)* 
User vs user 
Insulin vs Sulfonylurea 
 
1.17 (0.85-1.60) 
DPP-4i vs Sulfonylurea 1.13 (0.71-1.79) 
DPP-4i vs Insulin 0.84 (0.57-1.24) 
  Dementia-free subjects, HR (95% CI) 
User vs non-user 
Metformin 0.59 (0.49-0.71)† 0.75 (0.61-0.91)* 0.77 (0.61-0.98)* 
Insulin 1.54 (1.39-1.70)† 1.54 (1.39-1.71)† 1.35 (1.13-1.61)* 
Sulfonylurea 0.88 (0.67-1.15) 1.00 (0.77-1.32) 1.07 (0.76-1.52) 
DPP-4i 0.64 (0.54-0.75)† 0.71 (0.60-0.83)† 0.91 (0.66-1.27) 
GLP-1a  0.59 (0.36-0.97)* 0.68 (0.41-1.10) 0.65 (0.23-1.83) 
SGLT-2i 0.46 (0.20-1.05) 0.52 (0.22-1.23) 0.57 (0.20-1.56) 
User vs user 
Insulin vs Sulfonylurea 
 
1.45 (1.02-2.06)* 
DPP-4i vs Sulfonylurea 0.76 (0.42-1.37) 
DPP-4i vs Insulin 0.64 (0.43-0.97)* 
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5.5 USE OF METFORMIN AND DPP-4I IS CONNECTED TO SLOWER DECLINE 
IN MMSE SCORES AFTER DEMENTIA DIAGNOSIS (STUDY 5) 
In total, the study included 1,873 patients (4,732 observations) with DM diagnosis and AD or 
MixDem, who had at least one follow-up after dementia diagnosis.  
After applying weighting for dropout, the prevalent use of metformin (β 0.89, 95% CI 0.44-
1.33) and DPP-4i (0.72, 0.06-1.37) were associated with slower decline in MMSE scores 
compared to non-users (Figure 10, Table 10). In addition, insulin and sulfonylurea users 
experienced significantly faster decline in MMSE compared to DPP-4i users (insulin vs DPP-
4i -1.00, -1.95 to -0.04), (sulfonylurea vs DPP-4i -1.19, -2.33 to -0.04). Supplementary 
analyses with imputed missing MMSE scores between the observed follow-ups were 
consistent with the main analyses (Table 10). 
 
Figure 10. Changes in MMSE scores in users of antidiabetic medications. 
Based on weighted prevalent-user mixed-effect models analyses in propensity-score matched cohorts; 
Year represents follow-up time after baseline; Thin lines represent MMSE change in individual 
subjects (circles) with time, thick lines represent estimated MMSE change derived from the mixed-





Table 10. Annual point changes in post-dementia MMSE scores in incident and prevalent users of antidiabetic medication. 
Antidiabetic medication 
Weighted mixed-effect model Imputed weighted mixed-effect model 
MMSE point change with annual intervals 









Metformin x Time (514 user / non-user pairs) 0.89 (0.44; 1.33) 3.93 <0.001 0.88 (0.44; 1.32) 3.91 <0.001 
Insulin x Time (543 pairs) -0.03 (-0.48; 0.42) -0.13 0.90 -0.12 (-0.56; 0.32) -0.54 0.59 
SU x Time (640 pairs) -0.11 (-0.53; 0.31) -0.52 0.60 -0.13 (-0.56; 0.29) -0.62 0.53 
TZD x Time (67 users vs 260 non-users) 0.14 (-0.76; 1.04) 0.30 0.76 0.04 (-0.91; 0.98) 0.07 0.94 









Metformin x Time (101 vs 277) 0.70 (-0.16; 1.56) 1.59 0.11 0.53 (-0.31; 1.37) 1.23 0.22 
Insulin x Time (66 vs 263) -0.28 (-1.22; 0.67) -0.57 0.57 -0.37 (-1.34; 0.60) -0.74 0.46 
Sulfonylurea x Time (37 vs 147) -0.10 (-1.38; 1.17) -0.16 0.87 -0.19 (-1.48; 1.11) -0.28 0.78 
p, p-value; Z, standard score; β=beta coefficients (unstandardized coefficients) acquired from linear mixed-effects models with random intercept and slope; 
Time expressed in years of follow-up; Analyses were weighted for the inverse-probability of remaining in the study; Table summarizes incident (without 
history) and prevalent users (with and without history of medication use) who were 1:1 PS-matched with non-users in prevalent-user metformin, insulin and 
sulfonylurea analyses; Other cohorts were matched using 1:1 ratio; Matching criteria included age, sex, cohabitation, dementia type, Charlson comorbidity 
score, renal disease, diabetes type & duration, income category, use of statins, antihypertensive, antithrombotic, antipsychotic, antidepressant drugs, 




6.1 CHARACTERISTICS OF DIABETES IN DEMENTIA 
Study 1 described the patients diagnosed with dementia in Sweden between 2007-2012, 
among which 16.5% had comorbid DM. The prevalence concurs with the proportion of DM 
in >65 year-old Swedish population209 as well as other studies from Sweden67 and Europe7, 
210, 211. The results confirm DM as one of the most common comorbidities in patients with 
dementia. Further, the presence of DM was independently associated with lower age at 
dementia diagnosis, which is likely due to either overall higher risk of dementia in patients 
with DM3, or more frequent utilization of care leading to earlier dementia diagnosis212.  
DM patients had 21% and 17% higher probability of MixDem and VaD compared to AD, 
respectively, reflecting the overall higher cerebrovascular burden, and common combination 
of AD and vascular pathology in patients with DM61, 62. On the other hand, Lewy body 
dementias were negatively associated with DM. There is discordant evidence on DM and 
Lewy body dementias, where both negative association67, 72 and no connection68, 213 were 
observed. Conversely, DM is a risk factor for PD64, and the presence of PDD as well as 
combination of PDD and DM are associated with significantly higher mortality67, 214. Thus, 
while the lower activity of sympathetic nervous system may play some role215, it is more 
likely that our sample comprised significantly less patients with DM who survived until 
diagnosis of Lewy body dementia, compared to AD. 
Finally, patients with DM were 23% and 22% less likely to be prescribed ChEI and 
memantine, respectively. While the overall difference could be explained by a larger 
prevalence of VaD in DM patients where these drugs are not indicated25, 216, the results were 
confirmed in the analyses stratified by dementia type. Importantly, frailty and level of 
dependence may play a large role (rather than age or polypharmacy) in ChEI non-
prescription217. True, patients with DM were more commonly institutionalized (12.0% vs 
10.6%), but nursing home placement was not independently associated with DM in the 
multivariate models. Importantly, we had no measure of frailty or the activities of daily living 
to confirm the proposed hypothesis. In conclusion, the ChEI and memantine bring only 
modest improvements in cognitive functioning26, however the appropriateness of ChEI 
under-prescription in patients with DM should be further evaluated to as multiple non-




6.2 CHOLINESTERASE INHIBITORS AND MORTALITY 
In study 2 we followed-up the findings from study 1 and analyzed the survival associated 
with the use of ChEI, comparing patients with AD or MixDem who had or had not concurrent 
DM. ChEI were associated with 20-30% mortality risk reduction irrespective of DM status, 
suggesting similar overall effect across DM strata. Importantly, the findings were concordant 
with previous research149-151, however we have not observed a clear dose-response, likely due 
to different dose categorization (median split) and using low-dose group as reference. In the 
analysis of specific ChEI agents, only donepezil and galantamine exhibited mortality 
reduction, however the effect of galantamine was moderately stronger in patients with DM 
(up to 32% lower mortality risk, vs 26% in DM-free). Galantamine may have specific 
benefits for patients with DM, mediated through the cholinergic anti-inflammatory 
pathway155-157 or improving insulin sensitivity162. On the other hand, donepezil – the ChEI 
with lowest propensity for side effects153, was also associated with lower mortality, albeit to a 
lesser degree in patients with DM (up to 24%, vs 31% in DM-free). Furthermore, we found 
no association with mortality among rivastigmine users, likely due to inability to differentiate 
between the oral and transdermal application forms218, 219. In the whole-cohort analysis, ChEI 
as a class reduced the risk of DM-related mortality, suggesting that ChEI may reduce the risk 
of complications of DM that lead directly to patient death. The association was not consistent 
across all analyses; however, it supports the hypothesis that ChEI may help with maintaining 
glycemic targets. Whether such association may be mediated via cognitive stabilization and 
better self-management of DM remains to be elucidated141.  
The findings should be confirmed in different national cohorts, as the prescription in Sweden 
is quite frequent (~70% for ChEI, 20% for memantine)172, 173 and the utilization has been 
lower in the other European countries (3-20%)220, but is increasing221-223.  
6.3 CHANGES IN ANTIDIABETIC DRUG DISPENSATION 
In study 3, patients with dementia experienced a more substantial increase in insulin 
dispensation simultaneous with decrease in utilization of metformin and sulfonylurea. 
Overall, deprescribing is common among patients with dementia224, 225, and the decreasing 
metformin utilization correlates to the higher prevalence of renal failure in the older 
population226 - a major contraindication for metformin treatment227. Secondly, the risk of 
hypoglycemia associated with sulfonylurea4, 228 may constitute non-negligible risk of further 
cognitive decrements in patients with dementia179, 180 and sulfonylurea deprescription may be 
advised in patients with advanced age119. Hypoglycemia is an even larger concern in insulin46 
and Weiner and colleagues reported poorer health among insulin-treated older adults in the 
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US229. However, insulin has a specific position as second-line therapy in Sweden230, where 
the patients with dementia receive further nursing support with insulin injections, constituting 
a major differentiating factor. Furthermore, an insulin-specific benefit may be related to 
weight gain, as modest overweight may be protective in frail patients231, 232. 
Within the newer antidiabetic medications (DPP-4i, GLP-1a, SGLT-2i), both the overall use 
and initiation therapy were less common among patients with dementia. The preference of 
DPP-4i over GLP-1a may reflect higher tolerability of oral agents compared to subcutaneous 
injections and possible avoidance of further weight loss, which is a common symptom in 
patients at risk of cognitive impairment46, 233.  
These results suggest a Sweden-specific preference for insulin treatment in clinical 
management of T2DM or other/unspecified DM when cognitive impairment is present. 
Further clarification is needed, whether the lower utilization of incretin and SGLT-2i therapy 
in patients with dementia leads to “missing the benefits” of these medications234-236.  
Overall, our results reflect more conservative pharmacological management of T2DM in 
Swedish patients with dementia, however the assessment of glycemic targets and cognitive 
changes as well as comparisons with other national cohorts is necessary to determine the 
effectiveness of this approach. 
6.4 ANTIDIABETIC MEDICATIONS AND MORTALITY 
In the large cohort of patients with T2DM or other/unspecified DM and dementia, the use of 
insulin was associated with higher mortality, however the risk-increase was not consistent 
across analyses. Importantly, the discordant findings from the observational studies (higher 
risk)237, 238 and randomized studies (no risk increase)239 should be clarified. Gamble 
suggested, that the absence of variables on weight and glycemia in observational settings 
skew the results towards higher risk, which also extends to our findings240. Conversely, the 
lack of major difference in the mortality risk between dementia and dementia-free strata 
corroborates the major role of insulin in Sweden230 and may reflect well-managed insulin-
treated DM in patients with dementia. This is further supported by the comparative analyses 
in patients with dementia, where we found no mortality increase among insulin users 
compared to sulfonylurea or DPP-4i. However, higher hypoglycemia risk may have played a 
role in the 19% higher mortality among sulfonylurea-treated patients with dementia4, 228, as 
this was not observed in other studies239, 241.  
Furthermore, the first-line medication metformin was not associated with improved survival 




mortality risk) and the meta-analysis by Campbell and colleagues (28% lower risk)242. The 
patients with dementia using metformin were commonly co-treated with insulin during the 
follow-up (70% vs 52% in dementia-free), however it is unclear how would insulin mediate 
higher mortality risk among metformin users with dementia, as generally neutral239 or lower 
risk243 were found previously. Crucially, we lacked glycemic and biometric data, which may 
have confounded the relationship240.  
In the as-treated models, both GLP-1a (56% lower risk) and SGLT-2i (57% lower risk) were 
associated with lower mortality in patients with dementia, however no association was 
observed in DPP-4i users. In the observational studies of all-cause mortality, GLP-1a and 
SGLT-2i were comparable244, while lower mortality in GLP-1a users was reported compared 
to DPP-4i245. Moreover, Nyström and colleagues found larger mortality reduction in DPP-4i 
vs insulin users246, which our data corroborated only in the dementia-free cohort. On the other 
hand, the randomized trials have not concluded any significant difference in all-cause 
mortality reduction between the antidiabetic drugs239.  
The combined findings from studies 3 and 4 suggest, that the lack of DPP-4i effect in patients 
with dementia is a correlate to the late addition of DPP-4i, as insulin was more commonly 
prescribed in patients with dementia. On the other hand, the GLP-1a and SGLT-2i may have 
been utilized in a specific cohort of patients who benefitted from the weight-reduction46 and 
cardiovascular protection247 observed in these medications, respectively. Further, we had 
limited sample size of new users for some drug-to-drug analyses, and comparisons to non-
users may skew the results248, thus the findings should be confirmed in a population with 
higher dispensation of GLP-1a and SGLT-2i. 
6.5 ANTIDIABETIC MEDICATIONS AND MMSE CHANGE 
Study 5 evaluated changes in MMSE in patients with T2DM or other/unspecified DM and 
concurrent AD or MixDem.  
Firstly, we observed significantly slower decline in MMSE scores among the prevalent users 
of metformin. Metformin’s role in cognitive functioning in AD is complex, where both 
neuroprotective249-251 and pathology-accelerating properties252, 253 were noted in preclinical 
research. In clinical data, lower risk of dementia was observed in several studies114, 254, 255, 
however no association with MMSE was concluded in a recent meta-analysis256. Conversely, 
metformin was recently connected to slower decline in global cognition and executive 
function257 and another study concluded slower immediate and delayed memory decline, 
however only in patients with normal cognition and without ApoE-ε4 genotype88. Wu and 
colleagues have suggested differential cognitive properties of metformin through the 
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preclinical-MCI-AD continuum, with benefit limited to early stages88. The lack of effect in 
metformin initiators in our study corroborates such hypothesis, however the absence of 
genotypical and preclinical and MCI cohorts makes the comparison difficult. On the other 
hand, the slower MMSE change in the prevalent users speaks against metformin-associated 
cognitive damage in patients with AD or MixDem. 
Secondly, the prevalent users of DPP-4i experienced slower decline in MMSE compared to 
non-users. In observational setting, DPP-4i were associated with lower dementia risk235, 258, 
higher MMSE scores259-261 and slower memory decline in AD88. Conversely, the data from 
randomized studies are not encouraging106 and a recent clinical trial with linagliptin 
concluded no cognitive benefit among high-risk T2DM patients130. The discrepancy in 
cognitive findings may be related to timing of DPP-4i therapy in the AD continuum, similarly 
to metformin. Moreover, the comparison to non-users in observational studies may be too 
unspecific, however we reported slower MMSE decline in DPP-4i users even when 
compared to insulin and sulfonylurea. Conceptually, the greater risk of hypoglycemia in 
sulfonylurea and insulin46 may explain the negative association, however some findings in 
dementia-free patients dispute the link between hypoglycemia and cognitive dysfunction262.  
We had insufficient number of GLP-1a users, and further research on GLP-1a may provide 
different results even in randomized trials, as their potency and transport through blood-brain 
barrier is higher than DPP-4i263, 264 and the preclinical studies suggest amelioration in several 
AD-related pathways265. 
The metformin and DPP-4i findings are encouraging, however the difference in MMSE 
change was approximately 1 point, while the minimal clinically important decline in MMSE 
is estimated at 2-3 points266. Despite the rather modest differences, any preservation in 
cognitive functioning should be considered important, particularly when no disease-
modifying treatments are available. 
Thirdly, TZD, sulfonylurea or insulin use were not associated with significant change in 
MMSE decline compared to non-users. The TZD findings are in line with randomized 
clinical trials267, 268 and the observational data88. Study 3 corroborates general decrease in 
TZD utilization in patients with dementia, likely due to higher risk of cardiovascular and 
geriatric complications in TZD46. 
Our results do not suggest sulfonylurea use significantly affects MMSE scores compared to 
non-users, corroborating other studies concluding no effect on memory or global cognition88, 
269. Lastly, while some studies on insulin have concluded modest increase in dementia risk 




observational258 and randomized data79, 270 stating overall cognitive neutrality of insulin. The 
finding is important, as the insulin utilization in Sweden is particularly frequent. 
In conclusion, our results show that metformin and DPP-4i may be beneficial for overall 
cognitive functioning, while other medications have not affected a change in MMSE. A life-
course approach with analyses of specific cognitive domains should supplement our data to 
deconstruct the cognitive properties of antidiabetic medications. 
6.6 METHODOLOGICAL LIMITATIONS AND BIAS 
Study accuracy is determined by its precision (lack of random error – “how sure we are of the 
results?”) and validity (lack of systematic error – “do the results reflect truth?”)271, 272. The 
main sources of possible error in the thesis are described below. 
6.6.1 Selection bias 
Selection bias refers to the situation when the study participation is related to both the 
exposure and the outcome. Typically, selection bias occurs in the initial study phases where 
patients are recruited, or during the study course where patients may be lost during follow-up. 
The SveDem coverage of incident dementia cases was estimated at 36%186, however it is 
unlikely that due to nature of the disorder, the coverage will ever be complete. It is unknown 
how the patients participating in SveDem differ to the non-registered patients. However, the 
subjects included in quality registers generally tend to be healthier, male and in a higher 
socioeconomic position273, skewing the generalizability towards this population.  
In study 5 we analyzed MMSE change during follow-up, where a significant non-random 
dropout (“loss to follow-up”) occurs. This would constitute selection bias as patients with 
significantly different level of dementia severity were less likely to return for follow-up. 
Moreover, the irregularity of patients’ visits resulted in a dataset where some follow-ups were 
missing, however were preceded and followed with observed follow-ups. We addressed these 
issues using IPW for remaining in the study and imputation for in-between MMSE scores205 
and obtained reasonable estimates for the exposed and unexposed subjects. 
In studies 2-4, the outcomes (mortality and drug dispensation) were based on nationwide 
registers, reducing the possibility of selection bias due to loss to follow-up. However, the 
results still apply to a healthier cohort of patients with dementia, due to SveDem coverage. 
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6.6.2 Information bias 
Information bias primarily comprises measurement error leading to misclassification of 
exposure, outcome or other covariates271. 
SveDem provided diagnosis of dementia based on clinical criteria. The clinical diagnosis has 
overall lower sensitivity (~80% in AD, 20-70% VaD) compared to the gold standard – 
neuropathological examination274, 275, conversely the diagnoses set at baseline in SveDem are 
rarely changed (<5% of cases receive different dementia diagnosis during follow-up)172. 
We combined the records from the NPR and SPDR to define DM, as the inpatient NPR has 
generally high positive predictive value, but low sensitivity for DM diagnosis187. However, 
while combining the registers increased the proportion of DM coverage, the absence of 
information from primary care probably underestimated the prevalence of patients with 
lifestyle-only DM management. Moreover, we had no information on glycemic markers that 
would confirm the diagnoses. An ideal solution would be to merge SveDem with the National 
Diabetes Register, where the overall DM coverage is close to 90%175. In addition, the 
algorithm we used to categorize DM was based on the temporal relationships between the 
diagnoses (the earlier diagnosis considered correct) in combination with antidiabetic drug 
usage. In conflicting cases we grouped the patients into other/unspecified category, to 
increase the precision of T1DM and T2DM groups. It is very unlikely, that the algorithm 
misclassified patients with T1DM due to dependence on insulin dispensation. Moreover, the 
possible misclassification of T2DM and other/unspecified DM can be considered non-
differential due to equal sources and criteria used in all subjects. The algorithm’s predictive 
properties should be validated against the National Diabetes Register. 
Medication exposure was defined by the SPDR records, which reflect the medications 
dispensed from the pharmacy188. Importantly, SPDR does not allow for compliance analyses 
as the prescription-dispensation discordance is not recorded188. The national coverage and 
dispensation data contribute to high overall precision of the medication exposure. For higher-
quality information, observing the actual medication use or measuring drug concentrations in 
blood samples would be necessary. 
Distinction between new and all medication users was done in studies 2-5, as the inclusion of 
prevalent users can lead to bias (surviving on treatment)276. However, excluding prevalent 
users was not always possible due to low sample size of some medication users (studies 4 and 




study baseline for defining baseline incident exposure was deemed a reasonable compromise 
between sample size reduction and bias avoidance. 
Immortal-time bias describes a situation where during a period of the study follow-up, an 
outcome or an event that signifies censoring cannot occur. Usually, the distortion happens in 
pharmacoepidemiology when the period between study entry and medication initiation is 
misclassified or excluded from the analyses271, 277. In the studies 2 and 4, we have applied 
models with time-varying exposure, thus avoiding the immortal-time bias. Studies 3 and 5 
utilized only baseline drug exposure and time-constant modelling.  
Outcome misclassification may have occurred in study 2, where cause-specific mortality was 
explored. While we allowed for wide definition of DM-related mortality (E10-E14), it is 
possible that DM codes were less frequently denoted as the underlying cause190, thus 
underestimating the total number of DM-related deaths. On the other hand, there is no reason 
to suspect differential misclassification of the DM-related mortality among the ChEI exposed 
or unexposed patients. 
Information on other covariates was not conditional on the exposure or outcome categories, 
(e.g. duration of diabetes was extracted from the NPR in the same way for exposed, 
unexposed, patients who died and who survived), thus we consider the potential 
misclassification as non-differential, skewing the results predictably towards the null. 
6.6.3 Confounding 
Confounders are factors independently associated with both the exposure and the outcome 
and are not on the causal pathway between the exposure and the outcome. Thus, they can 
distort the analyzed relationships if not accounted for (“adjusted for”)271.  
A specific type of confounding present in non-randomized pharmacological studies is 
confounding by indication. It occurs when the study design cannot account for the decision-
making behind the initiation of certain treatment, and the decision-making is also related to 
the outcome278. Typical example is the spurious relationship between initiation of a more 
intensive treatment and worse outcomes, which is confounded by the severity of the patient 
condition279. It is likely that this type of confounding may bias our results to a certain degree, 
as we had no direct measure of the clinical reasoning, however we utilized several methods 
(e.g. covariate adjustment, PS-matching, IPW) to balance the characteristics between the 
exposed and unexposed.  
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Moreover, all thesis’ studies are affected by unmeasured variables, mainly the biochemical 
markers (e.g. hemoglobin A1c, kidney function, amyloid and τ markers), genotype 
(apolipoprotein-E ε4 allele) and lifestyle factors (exercise, smoking), and it is likely that we 
were not able to remove such confounding by adjusting for the observed variables. However, 





7.1 GENERAL CONCLUSIONS 
Subjects with DM constitute a distinct cohort among dementia patients, with earlier diagnosis 
of dementia and higher probability of VaD and MixDem dementia types. The prescription of 
symptomatic dementia medication is associated with longer survival in patients with DM and 
AD or MixDem, however these drugs are less commonly prescribed to this patient group. 
Moreover, the patients with dementia receive more conservative treatment for DM, reflected 
in the higher utilization of insulin after dementia diagnosis. Furthermore, the newer 
antidiabetic medications are associated with both lower mortality as well as slower global 
cognitive decline, while their prescription rate is lower in patients with dementia. 
7.2 SPECIFIC CONCLUSIONS 
1. The prevalence of DM in Swedish patients with dementia diagnosis is 16.5%. 
2. Compared to AD, the diagnosis of DLB and PDD is 34% and 56% less common, 
respectively, among patients with DM. 
3. ChEI class as well as donepezil and galantamine are associated with lower all-cause 
mortality among patients with DM and AD or MixDem dementia, however the 
association does not extend to CV mortality. ChEI use is associated with inconsistent 
decrease in DM-related mortality.  
4. Patients with dementia and T2DM or other/unspecified DM experience more frequent 
insulin usage, while the use of DPP-4i, GLP-1a and SGLT-2i increased less steeply in 
patients with dementia. 
5. Initiation of newer antidiabetic medication is less common in patients with dementia 
compared to dementia-free subjects. 
6. Insulin use in patients with dementia and T2DM or other/unspecified DM is associated 
with higher mortality, however the association is comparable to dementia-free subjects. 
7. New users of sulfonylurea with dementia experience higher mortality compared to non-
users, while the SGLT-2i are associated with protective effect on survival in this patient 
group. 
8. In patients with AD or MixDem with concurrent diagnosis of T2DM or other/unspecified 
DM, overall use of DPP-4i and metformin was associated with slower decline in MMSE 
scores compared to non-users. 
9. Compared to DPP-4i users, patients using sulfonylurea and insulin experienced faster 
decline in MMSE scores.    
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8 POINTS OF PERSPECTIVE 
The findings in this thesis support the role of diabetes mellitus as a major comorbidity in 
dementia. We observed a similar prevalence of DM in dementia patients as other studies, 
where approximately every 6th person with dementia is co-diagnosed with DM7. However, 
there is a large proportion of patients not included in SveDem, where the proportion of DM 
cannot be predicted. Secondly, while we focused mainly on the role of pharmacological 
treatments, there is an urgent need to develop comprehensive guidelines tailored for the 
clinical co-occurrence of DM and dementia. Furthermore, the thesis studies did not focus on 
T1DM in dementia, however T1DM is also associated with cognitive impairment48-50, and 
more research is needed on the care and clinical management in patients who have diagnosis 
of both dementia and T1DM.  
Our studies contribute to the observational evidence146, 147, 150, 151, that ChEI exhibit benefits 
beyond symptomatic cognitive improvement. Unfortunately, we had no information on 
markers of glucose metabolism, thus further studies should explore whether the survival 
benefit in DM patients may be due to better glycemic control and whether cognitive 
improvement mediates such association. Furthermore, the differences between ChEI 
utilization suggest care inequality between DM and DM-free patients, and the reasons for this 
difference should be clarified. Overall, our studies support ChEI prescription for patients with 
DM and AD or MixDem, with specific survival benefit with donepezil and galantamine. 
Further research avenues should include the role of insulin in patients with DM and already 
manifest dementia. Our studies reflect the Swedish approach to dementia care where insulin 
use in T2DM patients is more pronounced, however the patients receive nursing assistance 
with insulin injections, thus the results should be reproduced in other populations. 
Importantly, we observed no additional global cognitive decline in insulin users with AD or 
MixDem. Furthermore, the patients with dementia using insulin experienced moderate 
mortality increase, but comparable to the patients who were dementia-free. On the other 
hand, it is unclear how frequently the subclinical hypoglycemic events occur in patients with 
dementia, and whether these contribute to subtle changes unmeasurable by a cognitive 
screening test – such as MMSE. Additional studies into specific insulin regimens – short-
acting vs long-acting agents may clarify the relationship.  
The use of newer antidiabetic medications, such as DPP-4i, GLP-1a and SGLT-2i was 
associated with some survival and cognitive benefit, however the studies were limited by the 




dementia. Our results may contribute to more frequent utilization of these medications, 
however there are multiple research gaps that need to be filled. For example, the biological 
connections between the incretin system, SGLT-2i and AD pathogenesis should be clarified 
and the specific timing of the individual T2DM medications in the preclinical stages – MCI -
AD continuum should be examined. We hypothesize, that such inquiry may result in a 
treatment of both T2DM and AD with one pharmacological agent – providing individualized 
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